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Abstract 
Spinocerebellar ataxia type 1 is an autosomal dominant disorder caused by a 
CAG repeat expansion encoding a polyglutamine tract, where patients present 
with a lack of motor coordination including ataxia. The disease is characterized 
pathologically by loss of Purkinje cells (PCs) in the cerebellar cortex and 
neuronal loss in brain stem nuclei and cerebellar dentate nuclei. Besides 
expansion of the polyglutamine tract, other features of ATXN1 are critical for 
pathogenesis and severity of disease including phosphorylation of ATXN1 at 
S776. Mouse models expressing an expanded form of ATXN1, ATXN1[82Q] 
share initial disease features, such as ataxia, with mice with a normal repeat 
length with a phosophomimetic aspartic acid substitution, ATXN1[30Q]-D776. 
However, ATXN1[30Q]-D776 mice do not display late-stage, progressive disease 
features including PC death. In order to determine molecular pathways leading to 
the ataxic similarities as well as progressive disease differences in the models, I 
used RNA-sequencing to examine the cerebellar transcriptome. In addition to 
identifying candidate genes, Col18a1 and Cck, involved in PC – climbing fiber 
dynamics, I found splicing correlates with ataxia in the ATXN1[82Q] and 
ATXN1[30Q]-D776 mice. In order to validate RNA-seq targets and focus on the 
more biologically relevant splicing candidates, I developed and analyzed RNA-
seq from a conditional ATXN1[30Q]-D776 model. In addition, I used this model to 
examine disease recovery. Interestingly, I found a lack of recovery at older ages 
without PC death, suggesting older neurons are inherently less able to recover.
   iv 
 
Table of Contents 
 
Acknowledgements ................................................................................................. i 
Dedication .............................................................................................................. ii 
Abstract ................................................................................................................ iii 
Table of Contents ................................................................................................. iv 
List of Tables ........................................................................................................ vi 
List of Figures ...................................................................................................... vii 
Chapter 1: Introduction .......................................................................................... 1 
Chapter 2: Methods ............................................................................................. 19 
Chapter 3: RNA sequncing reveals roles for Cck, Col18a1 and Anks1b in 
Purkinje cell dysfunction in SCA1 mice ............................................................... 30 
Introduction ............................................................................................... 31 
Results ...................................................................................................... 34 
Discussion ................................................................................................. 64 
Chapter 4: Recovery of Conditional ATXN1[30Q]-D776 Mice ............................. 71 
Introduction ............................................................................................... 72 
Results ...................................................................................................... 74 
Discussion ............................................................................................... 101 
Chapter 5: Discussion ........................................................................................ 108 
Major Findings ........................................................................................ 109 
Future Directions ..................................................................................... 113 
   v 
 
Bibliography ....................................................................................................... 115 
Appendix 1: Table of significant ATXN1[30Q]-D776 vs ATXN1[82Q] gene 
expression results .............................................................................................. 125 
   vi 
 
List of Tables 
Table 3.1 
RNA-seq RNA Integrity Numbers ........................................................................ 36 
 
Table 3.2 
Total RNA-seq Reads .......................................................................................... 37 
 
Table 3.3 
Overview of Gene Expression Changes .............................................................. 40 
 
Table 3.4 
Overview of Splicing Changes ............................................................................. 43 
 
Table 3.5 
Target Gene List .................................................................................................. 48 
 
Table 3.6 
Top Gene Expression Networks .......................................................................... 60 
 
 
 
 
 
 
   vii 
 
List of Figures 
Figure 3.1 
Purkinje cell health at 12 weeks of age ............................................................... 35 
 
Figure 3.2 
RNA-seq read mapping efficiency ....................................................................... 39 
 
Figure 3.3 
Total up or downregulated genes ........................................................................ 42 
 
Figure 3.4 
Gene expression and target gene selection ........................................................ 44 
 
Figure 3.5 
Col18a1 cerebellar expression ............................................................................ 50 
 
Figure 3.6 
Reduction in CF synapses in ATXN1[30Q]-D776;Cck-/- PCs ............................... 52 
 
Figure 3.7 
Recovery of condATXN1[30Q]-D776 Rotarod deficit .......................................... 55 
 
Figure 3.8 
Diagram of Anks1b isoforms................................................................................ 56 
 
Figure 3.9 
Anks1b isoform 3 is downregulated in SCA1 models .......................................... 57 
 
Figure 3.10 
Top implicated pathways ..................................................................................... 62 
 
Figure 3.11 
Diagram of the CF-PC synapses forming with absence or enhanced levels of 
Col18a1 ............................................................................................................... 67 
 
Figure 4.1 
Tet-Off conditional model schematic ................................................................... 75 
 
Figure 4.2 
ATXN1 expression in condATXN1[30Q]-D776 lines ............................................ 77 
 
 
   viii 
 
Figure 4.3 
Motor coordination deficits in condATXN1[30Q]-D776 lines ................................ 78 
 
Figure 4.4 
Hind stance width in condATXN1[30Q]-D776 lines ............................................. 79 
 
Figure 4.5 
ATXN1 expression in condATXN1[30Q]-D776 after dox administration .............. 82 
 
Figure 4.6 
CF-PC extension is restored when condATXN1[30Q]-D776 is not expressed 
during cerebellar development ............................................................................ 85 
 
Figure 4.7 
Early stage disease recovery ............................................................................... 88 
 
Figure 4.8 
Early stage disease histology .............................................................................. 90 
 
Figure 4.9 
Mid stage disease recovery ................................................................................. 93 
 
Figure 4.10 
Mid stage disease histology ................................................................................ 95 
 
Figure 4.11 
Late stage disease recovery ................................................................................ 98 
 
Figure 4.12 
Late stage disease histology ............................................................................. 100 
 
Figure 5.1 
Model of ATXN1 disease mechanism ................................................................ 112 
 
 
 
 
 
 
   1 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
 
 
 
 
 
 
 
 
 
 
   2 
 
Spinocerebellar ataxia 
 
The spinocerebellar ataxias (SCA) are a group of autosomal dominantly inherited 
neurodegenerative conditions that have ataxia as a major component of the 
clinical presentation.  These patients usually have loss of coordination of the 
limbs and trunk, unstable gait, dysarthric speech, and nystagmus but may have 
other symptoms, including extrapyramidal dysfunction, dysautonomia, cognitive 
impairment, and motor and sensory impairments. The pathological process 
primarily involves the cerebellum, brainstem and spinal cord. There are 
approximately 30 different types identified to date with only about half having 
defined mutations.  A number of these diseases, including SCA types 1, 2, 3, 6, 
7, and 17 have an abnormal expansion of a CAG-repeat sequence, which codes 
for an expanded tract of glutamine (Q) residues within the mutated protein 
(Koeppen, 1998; Orr, 2000).   
 
Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant disorder caused 
by a CAG repeat expansion encoding a polyglutamine tract. It is characterized 
pathologically by loss of Purkinje cells (PC) in the cerebellar cortex and neuronal 
loss in brain stem nuclei and cerebellar dentate nuclei (Zoghbi and Orr, 1995). 
The SCA1 gene encodes ataxin-1, a protein of 792 to 826 amino acids 
depending on the number of CAG trinucleotides (Servadio et al., 1995). 
Unaffected alleles contain between 6-42 CAG repeats; the larger alleles 
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interrupted with 1-3 CAT (or histidine), while disease-related expansions range 
from approximately 40-80 pure polyglutamine residues (Chung et al., 1993). The 
age of onset for SCA1 is dependent on the repeat length, though typically occurs 
in the third or fourth decade (Zoghbi and Orr, 1995). Instability of the CAG repeat 
leads to genetic anticipation in SCA1, where age of onset decreases in 
subsequent generations as diseased allele repeat length increases from parent 
to offspring (Haines et al., 1984; Schut, 1950). Disease manifestations are 
progressive and there is no cure for SCA1, which is lethal 10-15 years after 
diagnosis.  
 
Mouse Models of SCA1 
 
Several mouse models have been generated in an effort to understand the 
molecular mechanisms underlying SCA1 disease and ataxin-1 function. Because 
SCA1 is a neurodegenerative diseases with an onset several decades into life, 
modeling in mice may not allow enough time for disease to develop during their 
relatively short life span.  This concern has been realized in a number of models, 
thus requiring over-expression of the transgene or a worsening of the genetic 
mutation (e.g., increasing the length of the CAG-repeat expansion) in order to 
create a clinical phenotype.  These manipulations create a potential for 
misinterpretation of results and require careful controls, such as lines with 
matched over-expression of normal allelic transgenes.  Another tactical issue is 
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whether to express the mutant transgene in all neurons or cells of the CNS, or to 
target critical populations such as the Purkinje cell (PC).  The advantage of the 
former approach is that it more closely models the human disease, but in turn it 
makes interpretation of mechanisms more complex.  The advantage of the latter 
approach is that PCs are critical cells for cerebellar function, they are the primary 
site of pathology in SCA1, and damage to them usually creates a behavioral 
phenotype.  In addition, PCs have an elaborate dendritic structure, which can be 
readily studied for morphological and even physiological alterations.  A 
disadvantage of this modeling is that human disease has a more complex 
pathology. 
 
The first mouse model was generated to test the CAG expansion, gain-of-
function hypothesis. Burright et al. (Burright et al., 1995) expressed the human 
SCA1 gene specifically in mouse PC using a Purkinje cell-specific Pcp2/L7 
promoter (Oberdick et al., 1990; Smeyne et al., 1991; Vandaele et al., 1991). 
Two lines were created with various repeat lengths; a control line with over-
expression of the normal interrupted allele containing 30 repeats, (CAG)12 
CATCAGCAT(CAG)15, while the expansion construct contained 82 uninterrupted 
CAG repeats. The control ATXN1[30Q] line, and the expansion ATXN1[82Q] line 
progeny both inherited the transgene either paternally or maternally and in all 
animals the repeat was stable and showed no change in repeat size. 
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After one year of age, the 30Q line had a normal phenotype, suggesting intact 
PC function. In contrast, the mutant 82Q lines developed reduced cage activity 
and general uncoordinated movements, which become more pronounced with 
age until they had clearly ataxic cage behavior at 12 weeks.  Footprint patterns 
indicated gait abnormalities and motor performance measured using a rotating-
rod apparatus was abnormal as early as 5 weeks (Clark and Orr, 2000). 
Pathologic changes were observed in the ATXN1[82Q] cerebellum as early as 
postnatal day 25 when clear cytoplasmic vacuoles were found in some of the 
somata of PC (Clark and Orr, 2000). The degeneration progressed with age and 
by 27 weeks the majority of PC had stunted, atrophic dendritic morphology. At 1 
year, the cerebellar cortex was dramatically decreased in size secondary to both 
atrophy and loss of PC, frequent heterotopic localization of PC in the molecular 
layer, and diminished calbindin immunoreactivity in surviving PCs.  Interestingly, 
PC loss was preceded by the ataxic phenotype. Adult mice expressing disease-
causing forms of ATXN1 in PCs also display alterations in climbing fiber (CF) 
innervation including a lack of CF terminals on PC dendrites and a reduction in 
CF-PC synaptic strength (Barnes et al., 2011; Duvick et al., 2010). In addition, 
ATXN1[82Q] PC accumulated ataxin-1- and ubiquitin-positive aggregates, or 
neuronal intranuclear inclusions (NII), that co-localized with the proteasome and 
the molecular chaperone, HDJ-2/HSDJ, demonstrating that there is ataxin-1 
misfolding in SCA1 disease (Cummings et al., 1998).    
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Öz et.al. demonstrated that changes in cerebellar neurochemical levels 
measured by proton magnetic resonance spectroscopy (1H MRS) can distinguish 
patients with SCA1 from controls (Öz et al., 2010). Specifically, patients exhibit 
decreased levels of N-acetylaspartate and glutamate, and increased levels of 
myo-inositol, which correlated with ataxia rating scores. These MRS biomarkers 
were similarly altered in ATXN1[82Q] mice indicating parallel neurochemical 
changes in the ATXN1[82Q] model and patients (Oz et al., 2010).  
 
To study the effect of mutant ataxin-1 expression under control of its endogenous 
promoter, a knock-in model was generated by inserting an expanded CAG 
trinucleotide repeat into the mouse Sca1 locus. The original model, Sca78Q/2Q, 
expressed endogenous levels of expanded ataxin-1 in the expected temporal and 
spatial patterns. However, the mice lacked any ataxic phenotype or 
neuropathological abnormalities. A second model was then generated with 154 
CAGs (Watase et al., 2002).  The Sca154Q/2Q phenotype included muscle wasting, 
ataxia, abnormal gait, severe kyphosis and premature death between 35 and 45 
weeks. Sca154Q/2Q animals displayed significant motor deficits by rotating-rod 
analysis at 5 and 7 weeks as well as impaired spatial learning deficits. This was 
intriguing as when an ATXN1 knock-out model was generated the mice did not 
display any ataxic symptoms but displayed learning deficits (Matilla et al., 1998). 
In addition, the Sca154Q/2Q mice exhibited a decrease in long-term potentiation at 
24 weeks. The Sca154Q/2Q animals were distinct from the ATXN1[82Q] model in 
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that they exhibited repeat instability similar to human patients (Watase et al., 
2003). Brains from Sca154Q/2Q animals were smaller than controls, though brain 
sections showed uniform atrophy rather than specific atrophy of the cerebellum 
more characteristic of SCA1 disease. While slight PC loss was observed, the 
molecular layer thickness was relatively intact even in 24-week-old animals. 
 
SCA1 disease reversal 
 
To determine if SCA1 disease is reversible, a conditional model of SCA1 was 
developed using the tetracycline-regulated (Tet) system (Zu et al., 2004). In this 
case, the Pcp2/L7 promoter drives the tetracycline-transactivator specifically in 
Purkinje cells, which can then bind a universally expressed tetracycline response 
element to induce expression of ATXN1[82Q] solely in PC. Administration of 
doxycycine (dox) abolishes this interaction and turns off expression of transgenic 
ataxin-1. Effects of reversal of transgene expression were assessed at early, 
mid, and late stages of disease. At the early stage, 6-week-old mice 
demonstrated a rotating-rod deficit that could be reversed after 6 weeks of dox 
treatment. In addition, PC pathology improved by assessment of molecular layer 
thickness and dendritic arborization, although heterotopic PC still were present. 
At mid stage disease, 12 week on – 4 week off animals continued to have 
rotating-rod deficits similar to 12 and 16 week-on animals. After 8 weeks and 12 
weeks of dox treatment, however, rotating-rod performance improved, but only 
   8 
 
partially. Interestingly, this 8-week timepoint coincided with the return of 
mGluR1α glutamate receptors at the Purkinje cell-parallel fiber synapses, albeit 
at a lower expression level. There was recovery of molecular layer thickness and 
improved arborization of PC dendrites demonstrating that halting ATXN1[82Q] 
expression at the time of typical onset of ataxia prevents the progression of and 
partially reverses degenerative changes in PC.  When the dox was given to 
animals at 32 weeks of age, there was no significant improvement of ataxia, but 
there was some improvement of PC pathology.  At all disease stages, the 
presence of ataxin-1[82Q]-containing NII was rapidly reversible with dox 
treatment. 
 
ATXN1 domains and localization 
 
ATXN1 contains a highly conserved domain of 12 amino acids at site 768-780, 
near the c-terminus (Carlson et al., 2009; de Chiara et al., 2009). This region 
contains a nuclear localization signal (NLS) at amino acids 771-774 (Klement et 
al., 1998), a 14-3-3 binding motif at amino acids 774-778 (Chen et al., 2003), and 
a UHM ligand motif (ULM) at amino acids 771-776 (de Chiara et al., 2009). ULMs 
are found only in proteins involved in RNA splicing (Corsini et al., 2007). ATXN1 
also contains a self-association domain between amino acids 495 and 605 
(Burright et al., 1997) and a 120 amino acid AXH domain (de Chiara et al., 2003). 
This AXH domain crystalizes as a dimer with an OB fold, which is a characteristic 
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of many oligonucleotide-binding proteins and further supports the idea that 
ATXN1 is an RNA-binding protein.  
 
Neuronal aggregates containing the mutant protein occur in many of the inherited 
polyglutamine disorders and have been suggested to be a common mechanism 
for neuropathology (Ross, 1997). To examine the role aggregates play in SCA1, 
Ataxin-1[77]Δ model was developed by deleting the self-association region of 
ataxin-1 (Klement et al., 1998). SCA1[77]Δ transgenic mice expressed ataxin-1 in 
the PC cytoplasm and nucleus, similar to ATXN1[82Q]  animals. However, 
SCA1[77]Δ mice did not develop NII.  The absence of NII, however, did not 
protect transgenic mice from developing PC pathology or ataxia. Indeed, 
SCA1[77]Δ had the same PC atrophy seen in ATXN1[82Q] animals and 
performed similarly to ATXN1[82Q] animals in behavioral examinations. Further 
studies crossed the ATXN1[82Q] to a transgenic mouse overexpressing HSP70 
chaperone protein (Cummings et al., 2001). These animals had improvement in 
ataxic phenotype and Purkinje cell morphology supporting the hypothesis that 
protein misfolding and impaired clearance of proteins might be contribute to 
pathogenesis in polyglutamine diseases. These studies suggested that protein 
misfolding and aggregation may contribute to pathology, but is not the primary 
form of pathogenicity in SCA1 (Klement et al., 1999). 
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To determine how cellular localization impacts disease an NLS mutant model 
was generated. Using the ATXN1[82Q] transgene, a lysine- to-threonine 
substitution at amino acid residue 772 disrupted the NLS function SCA1K772T 
(Klement et al., 1998). This resulted in transgenic mice that expressed ataxin-1 
primarily in the cytoplasm of Purkinje cells in contrast to control ATXN1[82Q] 
mice that expressed significant levels in both the cytoplasm and nucleus. More 
importantly, SCA1K772T mice did not develop ataxia, as measured by rotating-rod 
deficits or ataxic cage behavior and they had no cerebellar pathology (Klement et 
al., 1998). This data provided the first evidence that regions outside the 
polyglutamine tract are important for ATXN1 pathogenesis. Additionally, it 
provided the first data that ATXN1 must enter the nucleus to cause disease, 
suggesting that pathogenesis is mediated by an aberrant ATXN1 function in the 
nucleus. 
 
ATXN1 pathways 
 
To determine ATXN1 function in the nucleus, further studies investigated the role 
of binding partners in disease. Many proteins bind to ataxin-1 via its AXH 
domain, including the RORα-Tip60 complex (Serra et al., 2006). Mouse models 
expressing mutant forms of ataxin-1 expressed decreased levels of RORα and 
therefore decreased levels of RORα-mediated genes. To evaluate the role of 
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RORα in SCA1 pathogenesis, ATXN1[82Q] animals were crossed to staggerer 
heterozygous mice which lack one functional copy of Rora (sg/+). 
ATXN1[82Q]:sg/+ mice had more severe Purkinje cell pathology suggesting that 
depletion of Rora enhances SCA1 disease. Crossing ATXN1[82Q] animals to 
Tip60+/- animals transiently delayed the ATXN1[82Q] cerebellar degeneration by 
increasing RORa and RORa -mediated gene expression (Gehrking et al., 2011). 
 
ATXN1 also forms a native complex with a transcriptional repressor Capicua 
(Cic) in a large protein complex (Lam et al., 2006). Both wild-type and expanded 
ATXN1 form these complexes. Abolishing phosphorylation with an alanine 
substitution at serine 776 does not prevent these complexes from forming. 
Rather, Cic interacts with ATXN1 via the AXH domain (Kim et al., 2013). A study 
that crossed a transgenic line with a duplication of the murine ataxin-1-like 
protein to the 154Q- knock-in line found that increased levels of ataxin-1-like 
diminished disease severity in the knock-in line by displacing mutant ataxin-1 
from its native complex with Cic (Bowman et al., 2007). These findings support 
the concept that the selective neuropathology of SCA1 arises from modulation of 
a core functional activity of Ataxin-1.  
 
Wild-type and mutant ataxin-1 are known to interact with 14-3-3 proteins, and 
overexpression of 14-3-3 stabilizes ataxin-1 levels in cells and increases 
neurotoxicity of mutant ataxin-1 in Drosophila (Chen et al., 2003). Similarly, 
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Sca1[154Q/+] mice with a haploinsufficiency of 14-3-3-episilon show 
improvement of cerebellar pathology and motor phenotypes but no improvement 
of weight loss, respiratory function or premature death (Jafar-Nejad et al., 2011). 
Although both wild-type and mutant ataxin-1 were reduced in the cerebellum of 
these mice, they were not reduced in the brainstem, which is an area also 
affected in the Sca1[154Q] mice. This suggests that different pathogenic 
mechanisms may operate in different regions of the brain affected by the disease 
(Jafar-Nejad et al., 2011). 
 
Other studies implicate ATXN1’s role in gene expression. Since SCA1 and SCA7 
share a cerebellar degenerative phenotype, shared transcriptional changes were 
studied between the two knock-in models. Both Sca154Q/2Q and Sca7266Q/2Q mice 
significantly down-regulated insulin-like growth factor protein 5 (Igfbp5) in the 
granule neurons (Gatchel et al., 2008). This down-regulation in granule cells also 
was observed in the ATXN1[82Q] transgenic line, suggesting that it occurred by a 
non-cell-autonomous mechanism, as the change was a result of a pathogenic 
process initiated in Purkinje cells which solely expressed the mutant protein. 
 
Phosphorylation status critical for pathogenesis 
 
The amino acid sequence of ataxin-1 revealed several possible phosphorylation 
sites (Banfi et al., 1994). Further analysis by mass spectrometry identified a 
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serine at amino acid 776 as the major site of phosphorylation (Emamian et al., 
2003). This was also of interest due to its location in the highly conserved c-
terminus region mentioned above. In addition, evidence indicated that 
phosphorylation at this site modulated the stability of ATXN1 (Jorgensen et al., 
2009). A phosphomimetic aspartic acid mutation at this site was shown to 
increase the interaction with RNA-binding motif protein 17 (RBM17) to levels 
comparable to ATXN1[82Q]-S776 (Lim et al., 2008). Thus, ATXN1[82Q] protein 
or ATXN1 phosphomimetic with a normal repeat tract could similarly alter the 
normal ATXN1 function and increase the RBM17 mediated pathway.  
 
To examine whether phosphorylation regulates the function and pathogenicity of 
ataxin-1, mouse models either blocking phosphorylation by substituting alanine 
for serine (A776) (Emamian et al., 2003) or mimicking phosphorylation by 
substituting aspartic acid for serine (D776) (Duvick et al., 2010) were generated 
from the original 82Q and 30Q transgenes. At 5 weeks, ATXN1[82Q]-A776 was 
localized to the nuclei of PC similarly to ATXN1[82Q]. However, ATXN1[82Q]-
A776 mice formed substantially fewer NII compared to ATXN1[82Q] transgenic 
mice at 32 weeks. In addition, ATXN1[82Q]-A776 transgenic mice did not 
develop ataxic cage behavior, did not show deficits by rotating-rod testing, and 
had only mild PC pathology. These results indicate that the serine at position 776 
is critical for disease manifestation, while the expanded polyglutamine tract is not 
sufficient for disease. 
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On the other hand, ATXN1[30Q]-D776 transgenic mice had impaired motor 
coordination on the Rotarod compared to wild-type and ATXN1[30Q] control 
animals. The level of impairment was similar to that of ATXN1[82Q] animals and 
progressed as animals aged until they could no longer perform the task. 
Similarly, ATXN1[30Q]-D776 animals had a significantly widened gait typical of 
ATXN1[82Q] animals. This was intriguing because a single point mutation, 
mimicking phosphorylation, converted a wild-type protein to a pathogenic protein. 
ATXN1[82Q]-D776 mice had enhanced disease with significant PC atrophy and 
neuronal loss, while ATXN1[30Q]-D776 PC were atrophic but did not progress to 
significant neuronal loss. Therefore, ATXN1[30Q]-D776 can induce disease 
initiation and Purkinje cell dysfunction, but only mice expressing ATXN1 with an 
expanded polyQ tract have late stage disease and Purkinje cell death. 
 
Mutant ATXN1 Affects Gene Expression 
 
As previously indicated, clues from mouse models point to RNA-binding and 
protein-protein interaction as key for ATXN1 function and SCA1 pathogenesis. In 
addition, the fact that ATXN1 must enter the nucleus suggests that disruption of 
nuclear structures and functions may lead to changes in gene expression. In an 
effort to identify expression changes, ATXN1[82Q] cerebellar RNA was examined 
using a PCR-based cDNA subtractive-hybridization assay (Lin et al., 2000). This 
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study identified six genes that were significantly downregulated  in ATXN1[82Q] 
cerebellum including Icmt, Itpr1, Atp2a2, Slc1a6, Trpc3 and 5-phosphatase I, and 
one gene, Serpina1a, was upregulated. These were not global changes, as many 
other PC specific genes remained unchanged. In addition, these changes 
occurred between post-natal day 11 to three weeks of age, prior to detection of 
any histologic or behavioral abnormalities. 
 
A genetic screen in a Drosophila model of SCA1 identified several genetic loci 
capable of modulating SCA1 neurodegeneration (Fernandez-Funez et al., 2000). 
Many of the modifiers identified were those involved in protein folding, heat-shock 
response and ubiquitination common in polyQ diseases with misfolding. Other 
enhancer genes implicated oxidative and chemical stress play a role in 
pathology. Several of the modifiers identified were genes that encoded proteins 
with RNA-binding domains, suggesting RNA processing is a critical function of 
ATXN1 and alterations in this pathway lead to pathogenesis. An additional 
Drosophila study implicated DNA damage repair in SCA1 (Barclay et al., 2013).  
 
These data led to a larger, more in depth study of gene expression changes in 
disease models using microarrays at 5 and 12 weeks of age (Serra, 2004). This 
study compared gene expression profiles of affected ATXN1[82Q] to unaffected 
ATXN1[30Q] and ATXN1[82Q]-K772T. The gene lists were generated and 
compared, and 12 changes exclusively found to be altered in the ATXN1[82Q] 
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mice but not in either control, were considered relevant. Similar to Lin et al, most 
of the gene changes were downregulated including Homer3, carbonic anhydrase-
like sequence, G-substrate, Slc1a6, Itpr1, Purkinje cell protein 1, Atp2a3, EST 
(A1842002), homeotic protein Gtx. Three had increased expression including 
Tac1, Nrgn, and EST (AI852661). These findings implicate glutamate signaling 
pathways in pathogenesis. 
 
Towards identification of disease progression pathways 
 
Previous data indicates that even within the same neuronal cell type, PCs, 
disease initiation and early progression are distinct from late stage disease 
progression. ATXN1[30Q]-D776 induces disease initiation and dysfunction 
leading to ataxia but only in mice expressing the expanded polyQ tract does 
disease progress to late stage, PC death (Duvick et al., 2010). The lack of late 
disease progression to PC death in ATXN1[30Q]-D776 animals indicates that this 
later stage requires the presence of an expanded polyQ repeat. Therefore, we 
hypothesized that comparing ATXN1[30Q]-D776 with ATXN1[82Q] mice would 
identify PC pathways or molecules that correlate with PC dysfunction and ataxia, 
as well as features that distinguish disease in the two models. To identify 
molecular pathways leading to the ataxic similarities as well as progressive 
disease differences in the models, we used RNA-sequencing to examine the 
cerebellar transcriptome. Described in chapter 3 is RNA sequence analyses of 
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the cerebellar transcriptome from two ataxic SCA1 mouse models, ATXN1[82Q] 
and ATXN1[30Q]-D776. The analysis revealed that while ATXN1[82Q] and 
ATXN1[30Q]-D776 cerebella differed considerably in the expression of a number 
of genes, they had essentially identical alterations in RNA splicing. In addition, to 
validate RNA-seq targets and focus on the more biologically relevant candidates I 
developed a conditional ATXN1[30Q]-D776 mouse model and analyzed RNA-seq 
expression and splicing profiles. This led to the identification of a candidate 
ataxia RNA, Anks1b, which is mis-spliced in every ataxic model we tested. We 
propose that genes whose expression levels differ between ATXN1[82Q] and 
ATXN1[30Q]-D776 cerebella, such as Cck and Col18a1, encode proteins that 
contribute to phenotypes that differ between these two SCA1 transgenic lines. 
 
Assessing recovery of disease in conditional ATXN1[30Q]-D776 
 
Prior studies described the ability of conditional ATXN1[82Q] to recover from 
disease after halting expression of mutant ATXN1 (Zu et al., 2004). However, the 
extent of recovery was decreased as animals increase in age. It is unclear if age 
dependence recovery is due to prolonged exposure to mutant ATXN1 or if older 
neurons are inherently less able to recover. In addition, delaying ATXN1 
expression until after cerebellar development (which is completed 3 weeks after 
birth) greatly decreases disease severity (Serra et al., 2006). Since disease the 
progressive feature of disease is dependent on the presence of an expanded 
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polyQ tract, we set out to determine if the ATXN1[30Q]-D776 mice recover with 
age. We hypothesized that since the ATXN1[30Q]-D776 mice do not progress or 
activate cell death pathways, these mice would have enhanced recovery 
compared to ATXN1[82Q] at later ages. However, we found muted recovery at 
later ages suggesting that recovery is age dependent. These studies are 
described in chapter 4.  
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Mice 
The Institutional Animal Care and Use Committee approved all animal use 
protocols. ATXN1[82Q] (Burright et al., 1995), ATXN1[30Q]-D776, ATXN1[82Q]-
D776 (Duvick et al., 2010), conditional ATXN1[30Q]-D776 (Ebner et al., 2013), 
Pcp2-tTA (Zu et al., 2004) Cck-/- (Jax B6.129-Ccktm1Lcs/J) and FVB/NJ mice were 
housed and managed by Research Animal Resources under SPF conditions in 
an AAALAC-approved facility. Conditional ATXN1[30Q]-D776 mice were 
generated by adding a point mutation to TRE-ATXN1[30Q] construct, which were 
cloned in the same manner as TRE-ATXN1[82Q] mice (Zu et al., 2004). The 
transgene was linearized with Hind II and Xho I, gel isolated, purified by ethanol 
precipitation, and suspended in injection buffer (10 mM Tris-Cl [pH 8.0]; 0.1 mM 
EDTA) at a concentration of 4 ng/ml. Embryo injections were performed by the 
Mouse Genetics Laboratory, University of Minnesota. PCR and Southern blot 
analyses were used to identify transgene positive animals. PCR primer 
sequences include the following: TRE forward 5’- GTGAAAGTCGAGCTCGGT-3’, 
TRE reverse 5’- AGGCAGGCATTCGTTGCT-3’, tTA forward 5’- 
TTGCTCCATTGCGATGAC-3’, tTA reverse 5’- AACAGCGCATTAGAGCTG-3’. 
The Southern blot TRE probe was generated by digest of the TRE-ATXN1[30Q] 
construct with XhoI and EcoRI, isolating PhCMV-1 which contains the TRE 
sequence, followed by gel purification. Gene off mice were given 1.5mg/ml 
doxycycline (dox) (purchased from the University of Minnesota Boynton Health 
Service Pharmacy) in a 4% sucrose solution in their drinking water. Gene-on 
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animals were given 2% sucrose (to account for equal sucrose intake) for the 
same amount of time gene-off mice were administered dox. Pcp2 tTA/+ control 
mice were administered dox similar to the gene-on cohort. In all experiments 
involving the use of mice, animals of either sex were used. 
 
RNA Isolation 
Total RNA was isolated from dissected cerebella using TRIzol Reagent (Life 
Technologies, Carlsbad, California) following the manufacturer’s protocols. 
Cerebella were homogenized on ice in 500mL TRIzol reagent using an RNase-
Free Disposable Pellet Pestles in a motorized chuck. Once tissue was 
homogenized, 500mL TRIzol reagent was added for a total of 1mL TRIzol 
reagent per cerebella. Samples were then incubated for 5 minutes at room 
temperature to permit dissociation of nucleoprotein complexes. Phase separation 
was completed by adding 0.5mL chloroform, shaking vigorously for 15 seconds, 
and incubating at room temperature for 2-3 minutes. Samples were centrifuged at 
12,000 x g for 15 minutes at 4°C, allowing for collection of the clear upper 
aqueous layer into a new RNase-free tube. RNA was precipitated from the 
aqueous layer by the addition of 0.5mL 100% isopropanol, incubating at room 
temperature for at least 10 minutes and centrifugation at 12,000 x g for 10 
minutes at 4°C. The RNA pellet was washed with 75% ethanol, briefly vortexed, 
and centrifuged at 7,500 x g for 5 minutes at 4°C. The pellet was allowed to air-
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dry for 5-10 minutes at room temperature, making sure not to allow the pellet to 
dry completely. RNA was resuspended in 100-200ul RNase-free water by 
passing the solution through a pipette tip several times. RNA was incubated for 
10-15 minutes at 60°C and stored at -80°C. 
 
For RNA-sequencing RNA was further purified to remove any organic carryover, 
which can inhibit the enzymatic reactions used in Illumina library preparation and 
can increase the risk of failure of library generation. RNA was purified using the 
RNeasy Mini Kit (Qiagen, Venlo, Limburg), and following the manufacturer’s RNA 
Cleanup protocol. Briefly, buffer RLT and ethanol are added to the sample to 
promote selective binding of RNA to the RNeasy membrane. The sample is then 
applied to the RNeasy Mini spin column. Total RNA binds to the membrane, 
contaminants are efficiently washed away, and high-quality RNA is eluted in 
RNase-free water.  
 
cDNA Synthesis 
Random-primed cDNA was generated from 1μg RNA using the SuperScript VILO 
cDNA Synthesis Kit (Life Technologies) according to manufacturer’s protocols. 
Each reaction contained 4ul 5X VILO Reaction Mix, 2ul 10X SuperScript Enzyme 
Mix, 1ug RNA and DEPC-treated water to 20ul. Tube contents were mixed, 
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placed in a PCR block, and incubated at 25°C for 10 minutes, followed by 42°C 
for 60 minutes, then 85°C for 5 minutes to terminate the reaction. The cDNA 
generated was then diluted 1:5 for use in RT-qPCR.  
 
RT-PCR 
Primers were designed to exon 18 and 20 to amplify four of the splice forms of 
Anks1b. Primer sequences – left: gaaacgcattttggcatctt right: agtttttccggatgatgctg. 
cDNA was amplified with GoTaq Green Master Mix (Promega, Madison, 
Wisconsin) following manufacturer’s protocols for a 25ul reaction. Samples were 
amplified and removed from the thermal cycler (Bio-Rad, Hercules, California) 
after 22, 25 or 30 cycles. Bands were separated by gel electrophoresis and 
imaged on an UV transilluminator. 
 
RT-qPCR 
RT-qPCR reactions were completed using LightCycler 480 Probes Master Mix 
and hydrolysis probe (Roche, Penzberg, Germany) following manufacturer’s 
protocols. Primer sequences and probe combinations were generated using 
Universal ProbeLibrary for mouse Assay Design Center (Roche). Universal 
ProbeLibrary Mouse GAPD Gene Assay (Roche) was used as a control. Mouse 
Anks1b primers include the following: isoform 1 left: 
CCAGATTGCAACGCTCTTG right: CATGCTCTTCCAGGACTGCT probe #4, 
   24 
 
isoform 4 left: CGATGCAAGGAGGAGAAGAA right: CTCCCCAGTCCCCTGTCT 
probe #78, isoform 3 left: TGATATTCCCCGATCAAAGC right: 
CGTTCTGATTGGTCCAGATTT probe #34, common assay left: 
GACAGAGAATTCTACAAGCGATCC right: CAGAGGTGGGATGGTAGCC probe 
#12. To human ATXN1 left: AGAGATAAGCAACGACCTGAAGA right: 
CCAAAACTTCAACGCTGACC probe 67. To mouse Cck left: 
TGATTTCCCCATCCAAAGC right: GCTTCTGCAGGGACTACCG probe 9. To 
mouse Col18a1 left: ACCAGGACCAGGATTTGCT right: 
ATCAGAGCTTCGGGCTGTT probe 97. 
 
RNA-sequencing 
Whole cerebellar RNA from three biological replicates for each genoptype was 
isolated using TRIzol Reagent (Life Technologies) followed by purification with 
RNeasy Kit according to the manufacturer’s protocol (Qiagen) [methods detailed 
above]. Purified RNA was sent to the BioMedical Genomic Center at the 
University of Minnesota for quality control, including quantification using 
fluorimetry (RiboGreen assay, Life Technologies) and RNA integrity assessed 
with capillary electrophoresis (Agilent BioAnalyzer 2100, Algilent Technologies, 
Inc.) generating an RNA integrity number (RIN). All submitted samples had 
greater than 1ug total mass and RINs greater than 8. Library creation was 
completed using oligo-dT purification of polyadenylated RNA, which was reverse 
transcribed to create cDNA. The cDNA was fragmented, blunt‐ended, and ligated 
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to barcoded adaptors. The library was size selected to 320bp +/- 5% to produce 
average inserts of approximately 200bp, and size distribution validated using 
capillary electrophoresis and quantified using fluorimetry (PicoGreen, Life 
Technologies) and Q‐PCR. The libraries were then normalized, pooled and 
sequenced. ATXN1[82Q], ATXN1[30Q]-D776, and WT/FVB samples were 
sequenced on an Illumina GAIIX using a 76nt paired-end read strategy, while 
conditional ATXN1[30Q]-D776 samples were sequence on an Illumina HiSeq 
2000 using a 100nt paired-end read strategy. Data was stored and maintained on 
University of Minnesota Supercomputing Institute (MSI) Servers. Research 
Informatics Support Systems (RISS) bioinformaticians were available at MSI for 
analysis questions and support. 
 
Gene expression analysis with the Tuxedo pipeline was done using the Galaxy 
platform hosted by the MSI. Initial read quality was determined using FastQC 
(Andrews) to determine the following: basic statistics, per base sequence quality, 
per sequence quality scores, per base sequence content, per base GC content, 
per sequence GC content, per base N content, sequence length distribution, 
sequence duplication levels, overrepresented sequences, kmer content. Using 
the FastQC results, reads were trimmed to an acceptable length, e.g. per base 
sequence quality greater than 28. ATXN1[82Q] and ATXN1[30Q]-D776 reads 
were processed to remove contaminating adapter sequences. All paired-end 
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reads were correctly synchronized; this was checked using PE-Sync Report, a 
tool created by MSI.  
 
Reads were aligned to the mouse reference genome (Illumina igenomes mm9) 
with Tophat by using mostly default parameters, except a Std. Dev for Distance 
between Mate Pairs of 60 and using a gene annotation model only looking for 
supplied junctions. Differential gene expression was determined with Cuffdiff 
using default parameters. Splicing analysis was completed using GSNAP and 
DEXseq by using most default parameters. Genes/introns with a q≤0.05 were 
considered significant. Genome tracks were visualized with IGV. Results were 
graphed with CummeRbund. Pathway and clustering analysis was completed 
with Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, California) 
and DAVID Bioinformatics Resource (NIAID, NIH). 
 
Histology and Immunostaining 
Animals were deeply anesthetized and transcardially exsanguinated with PBS 
(pH 7.4) and perfused using 10% formalin (30 mL). Brains were post-fixed 
overnight in 10% formalin and subsequently placed in PBS at 4ºC before 
sectioning. The cerebellum was sagittally sectioned into 50 μm thick sections 
using a vibratome. Epitotopes were exposed using antigen retrieval by boiling 
sections four times for 10 sec each in 0.01M urea. The sections were blocked 
overnight in 2% normal donkey serum and 0.3% Triton X-100 in PBS. All 
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subsequent staining was carried out in 2% normal donkey serum and 0.3% Triton 
X-100 in PBS. The following primary antibodies were used: rabbit anti-ATXN1 
(11750) (Servadio et al., 1995) at 1:2000, rabbit, mouse or goat anti-calbindin 
(Santa Cruz) at 1:250, mouse anti-Vesicular Glutamate Transporter 2  (VGLUT2) 
(MAB5504, Millipore) at 1:1000, rabbit anti-Col18a1 (PA5-24199, Thermo 
Scientific) at 1:100, and (GA5, Cell Signaling) mouse anti-GFAP at 1:200. 
 
Sections were incubated for 24 hr in primary antibodies at 4ºC.  Following 
incubation, the sections were washed three times in PBS and exposed to 
secondary antibodies (DyLight 488, Dylight 549, and Dylight 649 - Jackson 
Immunoresearch, West Grove, PA) for 24 hr at 4ºC. Lastly, sections were 
washed three times in PBS and mounted onto charged slides (Colorfrost Plus, 
Fisher, Waltham, MA).  Fluorescently labeled tissue was imaged using a confocal 
Olympus 1000 IX inverted microscope.  
 
Quantification of Purkinje cell length and climbing fiber extension distance 
PC length and CF extension into the PC dendrites were measured using 20x 
confocal images from 50 μm cerebellar sections stained for calbindin and 
VGLUT2 from 6, 12, 16, 20, 24, 28, 32 and 36 week of age animals. Confocal 
image stacks of 16-μm depth and step size of 2 μm were captured from lobule VI 
and analyzed using the imaging program, Fluoview Viewer 1.7. The PC length 
was measured as the distance from the base of the PC soma to tip of the PC 
   28 
 
dendrite. CF extension into the molecular layer of lobule VI was measured from 
the base of the PC soma to the tip of the CF arbor, as previously described 
(Duvick et al, 2010). Six separate measurements of PC length and CF extension 
were taken from each image of the PC primary fissure and averaged.  On 
average, eighteen measurements were obtained from three midline sections from 
the lobule VI of each animal.  
 
Disease Severity Scale 
As an assessment of disease status the following disease severity scale was 
used: 0.5, near-normal but molecular layer (ML) somewhat thinner; 1, mild 
changes including heterotopic PCs, vacuoles in PCs, thinning of ML, largely 
confined to the posterior lobules; 2, similar to 1 but more widespread, heterotopic 
PCs more numerous and often higher in the ML; 3, widespread ML thinning, 
numerous heterotopic PCs involving anterior lobules nearly as frequently as 
posterior, mild PC loss, primarily in the posterior lobules; 4, severe 
disorganization of cerebellar cortex with generalized severe atrophy of ML and 
frequent heterotopic PCs and PC loss.  
 
Behavioral Analyses 
Motor ability was assessed using an accelerating Rotarod apparatus as 
previously described (Clark et al, 1997). Cohorts of 10 mice, 5 female and 5 
male, were tested using four trials per day, with a minimum of 10 minutes resting 
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period between trials, for 4 consecutive days. Each trial lasted a maximum of 10 
min, as the rod accelerated from 4 to 40 rpm over 5 minutes and then remained 
at the maximum speed of 40 rpm for an additional 5 minutes. Animals were 
scored in seconds for latency to fall from the rod. If an animal remained on the 
rod without running for three consecutive turns, it was considered a fall.  
 
Footprint analysis was completed using the DigiGait Imaging System (Mouse 
Specifics, Inc. Watertown, MA). Mice were placed onto the transparent treadmill 
moving at 25cm/sec and filmed for at least 6 seconds of continuous walking. 
Software analysis calculated the hind stance width in cm. 
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Chapter 3:  
RNA sequencing reveals roles for Cck, Col18a1 and Anks1b in Purkinje cell 
dysfunction in SCA1 mice 
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Introduction 
 
An important step towards understanding the molecular basis of 
neurodegenerative disease was the identification of genes in which mutations 
cause disease. While the genetic basis for many of the inherited 
neurodegenerative disease is known, it has remained challenging to link a 
specific molecular alteration with a disease-associated phenotype. Among the 
inherited neurodegenerative diseases are a group of disorders caused by the 
expansion of a CAG nucleotide repeat encoding a stretch of glutamine amino 
acids and, as a group, are known as the polyglutamine diseases. The 
polyglutamine neurodegenerative disease Spinocerebellar ataxia type 1 (SCA1) 
is a progressive autosomal dominant disorder caused by a CAG repeat 
expansion, where patients display loss of coordination of the limbs and trunk, 
unstable gait, dysarthric speech, and nystagmus pathologically associated with 
loss of Purkinje cells (PC) in the cerebellar cortex (Zoghbi and Orr, 1995).  
 
Mice expressing human Ataxin-1 with an expanded polyglutamine (ATXN1[82Q]) 
manifest a progressive form of disease similar to that seen in SCA1 patients. 
Besides expansion of the polyglutamine tract, other features of ATXN1 are critical 
for pathogenesis and severity of disease. Among these is phosphorylation of 
ATXN1 at S776, which when substituted with a phospho-resistant alanine 
renders ATXN1[82Q] nonpathogenic (Emamian et al., 2003). In contrast, placing 
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a potentially phospho-mimicking aspartic acid at position 776 enhances 
pathogenesis of ATXN1[82Q] and transforms wildtype ATXN1[30Q] into a 
pathogenic protein (ATXN1[30Q]-D776) (Duvick et al., 2010). An intriguing 
feature of disease in mice expressing ATXN1[30Q]-D776 is that while mice 
develop signs associated with early disease progression, including an ataxia 
similar to ATXN1[82Q] animals, disease in ATXN1[30Q]-D776 does not show the 
late-stage progression to PC death as seen in ATXN1[82Q] mice (Duvick et al., 
2010). Thus, comparing ATXN1[30Q]-D776 with ATXN1[82Q] mice affords an 
opportunity to identify PC pathways or molecules that correlate aspects of 
disease in common between these two SCA1 lines, as well as features that 
distinguish disease in the two models. 
 
Structural motifs identified in ATXN1, as well as cellular molecules that interact 
with ATXN1, indicate it functions in the nucleus as a regulator of transcription and 
RNA-processing with both playing critical roles in pathogenesis. Such motifs 
include the AXH (Ataxin-1/HBP1) domain that folds into an oligomer-binding 
(OB)-fold, forming both a putative RNA-binding and a protein-protein interaction 
surface (Chen et al., 2004; Kim et al., 2013), a nuclear localization signal (NLS) 
(Klement et al., 1998) that overlaps with or is immediately adjacent to a U2AF 
homology motif (UHM) ligand motif (ULM). UHM/ULMs are present in proteins 
associated with RNA splicing (de Chiara et al., 2009). Moreover, ATXN1 interacts 
with a variety of nuclear components including RNA (Irwin et al., 2005; Yue et al., 
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2001), several regulators of transcription including SMRT (Tsai et al., 2004), 
Capicua (Kim et al., 2013; Lam et al., 2006), Gfi-1 (Tsuda et al., 2005), and the 
Rora/Tip60 complex (Gehrking et al., 2011; Serra et al., 2006). Additionally, 
ATXN1 interacts with proteins involved in RNA processing such as the RNA 
splicing factors RBM17 (Lim et al., 2008) and U2AF65 (de Chiara et al., 2009), 
and p80 coilin involved in the assembly of U snRNPs (Hong et al., 2003). Of 
interest is the observation that ATXN1[82Q] as well as ATXN1[30Q]-D776 
interact more strongly with RBM17 than wild type Ataxin-1 (Lim et al., 2008). 
 
Based on a role of ATXN1 in regulating gene expression, we reasoned that RNA 
sequence analysis of the cerebellar transcriptomes of ATXN1[82Q] and 
ATXN1[30Q]-D776 mice would elucidate pathways that contribute to PC 
dysfunction in SCA1 mice. Results of this RNA sequence analyses presented 
here support a model whereby alterations in the level of expression of 
cholecystokinin and collagen 18a1 are uniquely enhanced in ATXN1[30Q]-D776 
cerebella and likely contribute to alterations in climbing fiber/PC synapse 
development. On the other hand, changes in RNA splicing patterns are identical 
in ATXN1[82Q] and ATXN1[30Q]-D776 mice. These latter results suggest that 
alterations in splicing, notably the splicing of ankyrin repeat and sterile alpha 
motif domain containing 1B (Anks1b or AIDA-1), contribute to the development of 
ataxia seen in both ATXN1[82Q] and ATXN1[30Q]-D776 mice.  
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Results 
 
Overview of SCA1 Mouse Cerebellar RNA-seq Analysis 
 
We harvested whole cerebellar RNA from ATXN1[82Q], ATXN1[30Q]-D776 and 
wt/FVB animals at 12 weeks of age; at this stage both disease models have 
ataxia with minimal Purkinje cell atrophy (Fig. 3.1).  
 
Samples were sent to the University of Minnesota Biomedical Genomics Center 
for library creation and Illumina GAIIx sequencing. In order to pass quality 
control, each sample was required to have an RNA integrity number (RIN) 
greater than 8; the cerebellar RNA-seq samples had RINs ranging from 8.3-9.4 
with an average RIN of 9.2 (Table 3.1). Using three biological replicates per 
genotype, a total of 157.4 million paired-end reads were generated with a 
minimum of 10 million reads per replicate (Table 3.2).  
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Figure 3.1 
 
 
 
 
 
Figure 3.1: Calbindin staining of representative sequenced genotypes shows 
minimal PC atrophy and absence of cell death at 12 weeks of age. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FVB ATXN1[82Q] ATXN1[30Q]-D776
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Table 3.1 
Genotype Replicate ID RIN 
WT/FVB 
FVB-1 9.2 
FVB-2 9.1 
FVB-3 9.2 
ATXN1[82Q] 
B05-414 9.1 
B05-415 9 
B05-416 9.2 
ATXN1[30Q]-D776 
D30-217 9.4 
D30-220 9.2 
D30-221 9.2 
conditionalD30 
38997 8.5 
38999 8.3 
38822 8.7 
conditionalD30+dox 
38823 9 
38824 8.8 
38831 9.1 
 
 
Table 3.1: RNA-seq samples RNA Integrity Numbers (RIN) indicated RNA 
sequenced was of high quality. 
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Table 3.2 
 WT/FVB Total 
Replicate	  ID FVB-­‐1 FVB-­‐2 FVB-­‐3  
Reads	  (millions) 13.77 17.61 13.13 44.51 
 ATXN1[82Q]  
Replicate	  ID B05-­‐414 B05-­‐415 B05-­‐416  
Reads	  (millions) 25.92 12.94 22.24 61.10 
 ATXN1[30Q]-­‐D776  
Replicate	  ID D30-­‐217 D30-­‐220 D30-­‐221  
Reads	  (millions) 17.47 18.41 15.94 51.82 
 condATXN1[30Q]-­‐D776  
Replicate	  ID 38997 38999 38822  
Reads	  (millions) 115.6 115.5 102 333.1 
 condATXN1[30Q]-­‐D776+dox  
Replicate	  ID 38823 38824 38831  
Reads	  (millions) 101.1 94.83 97.18 293.1 
 
 
Table 3.2: Amount of total RNA-seq reads by sample and genotype. 
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Initial read quality was determined using FastQC (Andrews). Reads were 
processed to remove adapter sequences and trimmed. Following data quality 
control and prepping, the samples were mapped to the UCSC mm9 mouse 
annotated genome (iGenomes, Illumina). Expression analysis was completed 
using the Tophat, Cuffdiff pipeline (Langmead et al., 2009; Trapnell et al., 2009, 
2010) on the Galaxy interface (Blankenberg et al., 2010; Giardine et al., 2005; 
Goecks et al., 2010). Alignment was completed using default parameters except 
for using a Std. Dev for Distance between Mate Pairs of 60 and a gene 
annotation model only looking for supplied junctions. Greater than 70% read 
pairs correctly mapped following these parameters (Fig. 3.2). The ATXN1[82Q] 
and ATXN1[30Q]-D776 samples had 10% less efficient mapping than wt/FVB 
(Fig. 3.2), due to processing to remove adapter sequences. Differential gene 
expression was determined with Cuffdiff using default parameters. 
 
Differential gene expression was completed in pairwise comparisons: 
ATXN1[82Q] vs. wt/FVB, ATXN1[30Q]-D776 vs. wt/FVB, and ATXN1[82Q] vs. 
ATXN1[30Q]-D776. ATXN1[82Q] and ATXN1[30Q]-D776 when compared to 
wt/FVB showed several thousand significant gene changes; a minimum of a two-
fold change decreased this number to several hundred (Table 3.3).  
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Figure 3.2 
 
 
 
Figure 3.2: Average mapping efficiency using Tophat or GSNAP by genotype. 
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Table 3.3 
Comparison Number of 
genes with 
expression 
changes 
Number of 
genes with 
expression 
changes, ≥2 
fold 
Number of 
genes with 
expression 
changes 
FPKM<3 
Number of 
genes with 
expression 
changes 
≥2 fold, 
FPKM<3 
ATXN1[82Q] vs 
wt/FVB 
6215 454 4789 225 
ATXN1[30Q]-
D776 vs 
wt/FVB 
5667 888 4385 434 
ATXN1[82Q]  
vs 
ATXN1[30Q]-
D776 
457 220 307 98 
 
Table 3.3: Overview of gene expression changes in SCA1 cerebella. Number of 
significant (q≤0.05) gene expression changes in pairwise comparisons, and gene 
expression changes with filters such as requiring greater than a fold change and 
removing low expressing genes by requiring an FPKM expression value of 
greater than 3. 
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The majority of ATXN1[82Q] and ATXN1[30Q]-D776 significant gene changes 
were downregulated in comparison to wt/FVB (Fig. 3.3).  
This is similar to previous results, which found downregulation of gene 
expression in SCA1 mouse models to predominate (Crespo-Barreto et al., 2010; 
Lin et al., 2000; Serra, 2004). Direct comparison of ATXN1[82Q] and 
ATXN1[30Q]-D776 datasets yielded 457 genes whose expression level 
significantly changed with 220 of those having a minimum of a two-fold change. 
Of the 457 genes differentially expressed between ATXN1[82Q] and 
ATXN1[30Q]-D776 cerebella, 157 genes were also significantly different in 
comparison to wt/FVB (Fig. 3.4A). 
 
Splicing analysis was accomplished by mapping with GSNAP/GMAP (Wu and 
Watanabe, 2005) and using DEXSeq for differential exon usage (Anders et al., 
2012). Pairwise comparisons showed global splicing changes in both 
ATXN1[82Q] and ATXN1[30Q]-D776 when compared to wt/FVB (Table 3.4).  
Interestingly, we observed a highly significant amount of overlap (Fisher’s exact 
test p=0) in splicing profiles with 6853 significant splicing changes in common 
between ATXN1[82Q] and ATXN1[30Q]-D776. Moreover, pairwise comparisons 
of the ATXN1[82Q] and ATXN1[30Q]-D776 yielded only 1 significant result, 
Slc20a1 (Table 3.4). However, only a single exon was identified as significantly 
changed in Slc20a1, and as it did not correlate with isoform specificity it was not 
further pursued as a target gene. 
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Figure 3.3 
 
 
Figure 3.3: Percentages of upregulated and downregulated genes relative to 
wt/FVB. 
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Table 3.4 
Comparison Number of 
genes with 
splicing changes  
ATXN1[82Q] vs 
wt/FVB 
8085 
ATXN1[30Q]-
D776 vs wt/FVB 
7464 
ATXN1[82Q]  vs 
ATXN1[30Q]-
D776 
1 
condATXN1[30Q]-
D776 vs 
condATXN1[30Q]-
D776+Dox 
96 
 
Table 3.4: Overview of splicing changes in SCA1 cerebella. Number of genes 
with significant (q≤0.05) splicing changes in pairwise comparisons. 
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Figure 3.4 
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Figure 3.4: Gene expression. (A) Venn diagram reporting significant (q<0.05) 
genes for each pairwise comparison. A total of 157 genes (red box) are 
significantly different in all three gene lists. (B) The majority of shared changes go 
in the same direction (125 of 157 or 79.6%). Further candidate selection including 
moderate FPKM values of ≥3.0, inclusion in a PC enriched translated mRNA list, 
and recovery in the conditional ATXN1[30Q]-D776 model after cessation of gene 
expression resulted in identification of two target genes, Col18a1 and Cck. RNA-
seq expression results for Col18a1 (C) and Cck (D). 
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In summary, these analyses revealed a considerable number of differences in 
gene expression in cerebellar RNA isolated from ATXN1[82Q] and ATXN1[30Q]-
D776 when compared to wt/FVB cerebellar RNA. In addition, there were a large 
number of genes whose cerebellar expression differed between ATXN1[82Q] and 
ATXN1[30Q]-D776 mice. This suggests expression differences may underlie 
some of the phenotypic differences in the models. In contrast, while ATXN1[82Q] 
and ATXN1[30Q]-D776 each had a substantial number of RNAs whose splicing 
differed when compared to wt/FVB cerebellar RNA, when compared to each 
other, ATXN1[82Q] and ATXN1[30Q]-D776 showed virtually identical splicing 
patterns at 12 weeks of age. Thus, splicing may correlate with common aspects 
of disease in the two models. 
 
Col18a1 and Cck Contribute to Enhanced CF synapse on PC Soma in 
ATXN1[30Q]-D776 Mice 
 
Since cerebellar RNAs from ATXN1[82Q] and ATXN1[30Q]-D776 mice differed 
considerably in the number of RNAs with altered levels of expression, we 
reasoned that a detailed examination of the 157 RNAs that differed significantly 
in expression level between ATXN1[82Q] and ATXN1[30Q]-D776 mice and with 
each compared to wt/FVB would reveal proteins that contribute to the differences 
in phenotype (Fig. 3.4 A).  Most of the RNAs in ATXN1[30Q]-D776 and 
ATXN1[82Q] that differed significantly in expression compared to wt/FVB 
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changed in identical directions, i.e. 59 were upregulated and 66 were 
downregulated in both ataxic models relative to wt/FVB (Fig. 3.4 B). We further 
reasoned that focusing on the remaining 32 genes that responded in opposite 
directions ATXN1[30Q]-D776 and ATXN1[82Q] relative to wt/FVB would reveal 
genes whose expression likely underlies the differences between the two ataxic 
models (Fig. 3.4 B & Table 3.5). 
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Table 3.5 
Gene Name  Wildtype ATXN1[82Q] 
ATXN1[30Q]
-D776 
condATXN1[30Q]-
D776 recovery 
6030405A18Rik 1.17113 0.766082 2.09542 no 
AI593442 8.55231 6.96229 14.4775 no 
B3gat1 18.9886 15.5848 24.3486 yes 
Camk2a 31.3633 15.394 61.9661 yes 
Cck* 45.4973 20.7823 265.736 yes 
Coch 3.2505 4.70457 1.99663 no 
Col18a1* 19.2714 6.04303 36.3187 yes 
Col5a1 2.61754 0.607579 5.07817 yes 
Cpne4 0.908513 0.50765 1.67215 no 
Elfn2 4.22289 2.75463 6.3964 no 
Enc1 6.8663 4.2024 14.1487 no 
Fzd7 17.3004 20.9037 13.3422 no 
Grin2b 0.825747 0.557256 1.42982 no 
Hrh3 7.28959 5.82844 11.4311 no 
Hs3st4 1.29894 0.82005 3.16942 no 
Ildr2 3.30077 2.62193 4.27992 no 
Lmo7* 2.82506 2.07159 4.03173 yes 
Mal2 3.3759 1.94973 5.06744 no 
Miat 3.74863 2.65277 8.67382 no 
Necab2 2.46155 1.50403 4.89033 no 
Pde2a 13.6148 11.1162 18.8879 no 
Rasgrf2 1.96399 1.21796 3.46647 no 
Resp18 38.3563 30.6832 54.0057 no 
Rgs4 9.51738 7.32466 12.3916 yes 
Slc18a2 1.64983 1.09999 2.66408 no 
Sorcs2 3.68513 2.92577 6.71481 no 
Spnb3 136.922 114.395 193.129 yes 
Spry4 2.38957 1.7532 3.29265 yes 
Syt16 1.60265 0.932945 2.78156 no 
Tph2 0.885536 0.157855 4.78416 no 
Wnt3 5.86374 4.35632 7.75199 yes 
Pcp2* 668.13 534.349 859.828 no 
 
Table 3.5: Full gene list of 32 genes with expression (FPKM) differing in opposite 
directions. Asterisks denote PC enriched translated mRNA (Heiman et al., 2008). 
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Of the 32 genes whose expression differed in opposite directions, two were 
selected as being of specific interest, cholecystokinin (Cck) and collagen, type 
XVIII, alpha 1 (Col18a1). First of all, detection of both transcripts was robust, 
these genes were moderately expressed having FPKM values of ≥3.0 (Mortazavi 
et al., 2008). Importantly, both transcripts are in a list of PC enriched translated 
mRNAs (Heiman et al., 2008). In addition, expression of Cck and Col18a1 was 
restored to wt/FVB levels in a condATXN1[30Q]-D776 mice upon cessation of 
transgene expression (Fig. 3.4 C). Lastly, the differences in expression of these 
two genes were dramatic in ATXN1[82Q] cerebellar RNA compared to 
ATXN1[30Q]-D776 samples. Cck expression was elevated in ATXN1[30Q]-D776 
samples, being roughly five fold higher than in wt/FVB RNA and 12-fold higher 
than in ATXN1[82Q] cerebellar RNA (Fig. 3.4 C). Expression of Col18a1 
compared to wt/FVB was 3-fold lower in ATXN1[82Q] and almost 2-fold higher in 
ATXN1[30Q]-D776 cerebellar RNA samples (Fig. 3.4 D). We examined Col18a1 
protein expression in ATXN1[82Q], ATXN1[30Q]-D776 and wt/FVB cerebella. In 
accordance with the RNA-seq data, only the ATXN1[30Q]-D776 PC bodies and 
dendrites stain positive (Fig. 3.5).  
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Figure 3.5 
 
Figure 3.5: Col18a1 expression in mouse cerebella. Calbindin (red) and Col18a1 
immunostaining (green) showing upregulation of Col18a1 in ATXN1[30Q]-D776 
and positive staining in the PC bodies and dendrites. 
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While Col18a1, and its proteolytically derived fragment endostatin, are critical for 
proper formation of CF synapses on the dendrites of PCs (Su et al., 2012), little is 
known regarding the role of Cck in the CNS, and in particular the cerebellum is 
less well understood (Matsui et al., 1993; Wood et al., 1988). To determine if Cck 
overexpression has a role in any of the cerebellar phenotypes in ATXN1[30Q]-
D776 animals, we bred them to Cck-/- mice. The ATXN1[30Q]-D776/Cck-/- mice 
exhibit ataxic cage behavior as early as 5 weeks, similar to ATXN1[30Q]-D776 
animals. At 12 weeks of age, we examined cerebella of ATXN1[30Q]-D776/Cck-/- 
for histopathology. While no molecular layer changes were observed, there was a 
significant decrease in the number of CF puncta on the PC body in comparison to 
ATXN1[30Q]-D776 mice (Fig. 3.6). 
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Figure 3.6 
 
Figure 3.6: Reduction in CF synapses in ATXN1[30Q]-D776;CCK-/- PCs. Graph 
shows number of PCs with >10 VGLUT2 synapses (left axis, grey bars) and 
average number of VGLUT2 synapses per PC soma (right axis, black bars) in 
mice 12 weeks of age; wt/FVB (n=83 PCs), ATXN1[30Q]-D776 (n=132 PCs), 
ATXN1[30Q]-D776;CCK-/- (n=129 PCs). Below are representative images of 
isolated PCs (calbindin, red) and VGLUT2 (green). 
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Alterations in Splicing of Anks1b Correlate with Ataxia in SCA1 mice 
 
Both ATXN1[82Q] and ATXN1[30Q]-D776 mice develop ataxia to a similar level 
of severity (Duvick et al., 2010), both ATXN1[82Q] and ATXN1[30Q]D776 
proteins interact strongly with the splicing factor RBM17 (Lim et al., 2008), and 
the pattern of splicing we detected by sequencing of cerebellar RNA from these 
two lines essentially overlapped (Table 3.4). Therefore, we hypothesized that 
common splicing alterations underlie development of ataxia in ATXN1[82Q] and 
ATXN1[30Q]-D776 animals. However, the large number of RNAs (6853) whose 
splicing is significantly altered in common in ATXN1[82Q] and ATXN1[30Q]-D776 
compared to wt/FVB mice complicates the identification of candidate “ataxia” 
RNAs.  
 
As a strategy to hone in on candidate RNAs whose altered splicing might 
contribute to ataxia in these mice, we sequenced cerebellar RNA from 
condATXN1[30Q]-D776 tet-off mice (Ebner et al., 2013). Whole cerebellar RNA 
was harvested from three biological replicates of gene-on condATXN1[30Q]-
D776 at 12 weeks-of-age and condATXN1[30Q]-D776 animals that were allowed 
to age for 6 weeks with the gene on and then aged an additional six weeks with 
the ATXN1[30Q]D776 gene off. Prior to RNA isolation, all animals were assessed 
for motor deficit via the accelerating Rotarod. Importantly, six-week gene on/six-
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week gene off condATXN1[30Q]-D776 animals fully recovered the ability to 
perform this test (Fig. 3.7, condATXN1[30Q]-D776 model discussed further in 
chapter 4).  
 
RNA was prepared for sequencing as above. However, in this case sequencing 
was performed using an Illumina HiSeq 2000 with a 100nt paired-end read 
strategy. Splicing analysis revealed 96 genes with significant splicing changes 
(Table 2), 77 of which overlap with the 6854 common splicing changes. Gene 
ontology analysis using DAVID (Database for Annotation, Visualization and 
Integrated Discovery) (Huang et al., 2008, 2009) identified 16 of the 96 genes 
with a GO term synapse, consistent with the concept that synaptic dysfunction(s) 
contribute to development of ataxia in these mice (Barnes et al., 2011; Hourez et 
al., 2011). This included ankyrin repeat and sterile alpha motif domain containing 
1B (Anks1b), which was also included in the ATXN1[82Q] and ATXN1[30Q]-
D776 vs. wt/FVB significant splicing lists. 
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Figure 3.7 
 
 
 
Figure 3.7: Recovery of condATXN1[30Q]-D776 Rotarod deficit and ataxia after 
six weeks of treatment with dox to turn the gene off. 
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Figure 3.8 
 
Figure 3.8: Diagram of Anks1b isoforms and locations of structural domains. 
Arrows represent primer locations for either RT-PCR or q-PCR. 
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Figure 3.9 
 
 
 
 
Figure 3.9: Anks1b isoform 3 is downregulated in SCA1 models. (A) RT-PCR of 
Anks1b isoforms 1-5 after 25 cycles shows a decrease in isoform 3 (top band) in 
condATXN1[30Q]-D776 that increases after treatment with dox. (B) Graph shows 
relative expression (RT-qPCR) of isoform 3 in wt/FVB, ATXN1[82Q], 
ATXN1[82Q]-D776, ATXN1[30Q]-D776, condATXN1[30Q]-D776 and 
condATXN1[30Q]-D776 + dox cerebella at 12 weeks of age. 
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To validate splicing changes in each of the mouse models, we designed RT-PCR 
primers to identify splicing changes in a region that has isoform specific exon 
inclusion (Fig. 3.8, dashed box). RT-PCR showed a reduction in isoform 3 levels 
in condATXN1[30Q]-D776 cerebellar RNA that was restored with dox treatment, 
while the other isoform levels stayed consistent (Fig. 3.9 A). We also designed 
RT-qPCR assays to quantify several of the isoforms including 1, 3, 4, and a RT-
qPCR assay detecting an exon in common among all isoforms (Fig. 3.8). 
Isoforms 2 and 5 had no unique exons in which to base a test. The common 
assay showed changes consistent with RNA-seq data (data not shown). 
Interestingly, isoform 3 showed reduced levels in each ataxic mouse model, 
which was rescued to wt/FVB levels in the condATXN1[30Q]-D776 treated with 
dox (Fig. 3.9 B). Thus, expression of isoform 3 of Anks1b in six different mouse 
lines correlated perfectly with the presence or absence of ataxia with a 
decreased level of Anks1b isoform 3 denoting lines with ataxia. 
 
Implicated Pathways 
 
In addition to identifying candidate genes, pathway analysis using Ingenuity® 
Pathway Analysis (IPA®) software was completed to determine if any pathways 
were predominantly affected. Core analysis was completed by setting minimum 
values at 2 FPKM, and 0.05 false discovery rate (q-value).  
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First, we examined the top diseases and biological functions. IPA categorizes the 
Top Diseases and Bio Functions into the following three groups: Diseases and 
Disorders, Molecular and Cellular Functions, and Physiological System 
Development and Function. As may be expected, neurological diseases top the 
diseases and disorders section for the ATXN1[82Q] and ATXN1[30Q]-D776 
compared to wt/FVB. When I examined top networks (summarized in Table 3.6), 
five were identified in the ATXN1[82Q] vs wt/FVB comparison, all with a score of 
28 including one, hereditary disorder, neurologic disease, psychological disorder, 
and two, RNA post-transcriptional modification, cellular assembly and 
organization, nucleic acid metabolism. In the ATXN1[30Q]-D776 vs wt/FVB 
comparison the top networks are one, connective tissue disorders, 
developmental disorders, hereditary disorders and two, RNA post-transcriptional 
modification, RNA damage and repair, molecular transport. Direct comparison of 
ATXN1[30Q]-D776 and ATXN1[82Q] identified hematological system 
development and function, developmental disorder, hematological disease as the 
top network and hereditary disorder as the top disease and disorder. The 
condATXN1[30Q]-D776 treated with or without dox, once again identified 
neurological disease as the top disease and disorder and identified cell death 
and survival, cellular assembly and organization, cellular compromise as the top 
network. 
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Table 3.6  
Comparison Top Networks IPA score 
ATXN1[82Q] vs 
wt/FVB 
Hereditary disorder, neurologic disease, psychological 
disorder 28 
RNA post-transcriptional modification, cellular assembly 
and organization, nucleic acid metabolism 28 
Cancer, cellular movement, cellular compromise 28 
Cellular growth and proliferation, reproductive system 
development and function, cancer 28 
Connective tissue disorders, dental disease, 
developmental disorder 28 
ATXN1[30Q]-
D776 vs wt/FVB 
Connective tissue disorders, developmental disorders, 
hereditary disorders 29 
RNA post-transcriptional modification, RNA damage and 
repair, molecular transport 29 
Cell death and survival, dermatological diseases and 
conditions, developmental disorder 29 
Post-translational modification, cell-mediated immune 
response, cellular movement 29 
Hematological disease, organ morphology, skeletal and 
muscular system development and function 27 
ATXN1[30Q]-
D776 vs 
ATXN1[82Q] 
Hematological system development and function, 
developmental disorder, hematological disease 41 
Cell cycle, cellular development, cell death and survival 31 
Cell-to-cell signaling and interaction, nervous system 
development and function, neurological disease 29 
Gene expression, behavior, cell-to-cell signaling and 
interaction 28 
Cancer, cellar development, tumor morphology 28 
condATXN1 
[30Q]-D776 
treated vs 
untreated 
Cell death and survival, cellular assembly and 
organization, cellular compromise 43 
Cellular assembly and organization, cellular function and 
maintenance, audiotry and vestibular system development 38 
Skeletal and muscular system development and function, 
organismal development, developmental disorder 36 
Cell-to-cell signaling and interaction, nervous system 
development and function, auditory disease 34 
Auditory disease, hereditary disorder, neurological disease 32 
 
Table 3.6: Top associated networks from IPA analysis. 
 
   61 
 
Since the networks and diseases and bio functions had similar results in the 
comparisons, I next focused on canonical pathways. Both ATXN1[82Q]  vs 
wt/FVB and ATXN1[30Q]-D776 vs wt/FVB have molecular mechanisms of cancer 
as the top canonical pathway affected (Figure 3.10). This includes major 
signaling pathways that contribute to malignant phenotypes such as GPCR 
signaling, Ras/integrin signaling, Akt signaling, TGF-β/BMP signaling, WNT 
signaling, Notch and Hedgehog signaling and Death receptor signaling. The most 
highly upregulated genes were Jun and Fos, while the most downregulated 
genes were Camk2a and Bmp5 (Figure 3.10). The direct comparison of 
ATXN1[30Q]-D776 vs ATXN1[82Q] resulted in the Cck/Gastrin pathway being 
the most affected, reinforcing our selection of Cck as a top candidate. The 
condATXN1[30Q]-D776 treated with or without dox identified axonal guidance, 
synaptic long term depression, and synaptic long term potentiation (Figure 3.10). 
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Figure 3.10 
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Figure 3.10: Top pathways associated with gene expression changes in SCA1 
mice. Canonical pathway name followed by the number of molecules changed in 
the gene list from total molecules in the pathway. Black bar represents gene 
upregulation and gray bar represents gene downregulation. The genes listed are 
the top changed genes up and down respectively. 
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Discussion 
 
RNA-seq reveals more expression similarities in ATXN1[82Q] and 
ATXN1[30Q]-D776 than anticipated 
 
RNA sequence analyses of the cerebellar transcriptome from ATXN1[82Q] and 
ATXN1[30Q]-D776 compared to wt/FVB generated large significant gene 
expression lists with 6215 and 5667 significant gene expression changes 
respectively. We also found that a great number of these genes (4459) overlap, 
e.g. they are found in both groups. In addition, many of the same pathways and 
networks were implicated using pathway analysis. 
 
While many genes were differentially changed in ATXN1[82Q] and ATXN1[30Q]-
D776 it was surprising to find that extent of similarity. It suggests that despite 
lacking an expanded polyglutamine tract, the ATXN1[30Q]-D776 is a good model 
of SCA1 disease and can be used to further our understanding of the differences 
between initial disease features and late stage disease features like PC death. 
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RNA-seq expression differences reveal roles for Cck and Col18a1 in CF/PC 
synapse dysfunction 
 
RNA sequence analyses of the cerebellar transcriptome from two ataxic SCA1 
mouse models, ATXN1[82Q] and ATXN1[30Q]-D776, in comparison to each 
other as well as to control wt/FVB revealed that while ATXN1[82Q] and 
ATXN1[30Q]-D776 cerebella differed considerably in the expression of a number 
of genes, they had essentially identical alterations in RNA splicing. Thus, we 
propose that genes whose expression levels differ between ATXN1[82Q] and 
ATXN1[30Q]-D776 cerebella encode proteins that contribute to phenotypes that 
differ between these two SCA1 transgenic lines. In contrast we suggest that the 
common alterations in splicing promote phenotypes shared by ATXN1[82Q] and 
ATXN1[30Q]-D776 mice, most notably the motor deficits associated with the 
ataxia seen in both lines.  
 
In the case of RNAs whose expression differed significantly between 
ATXN1[82Q] and ATXN1[30Q]-D776 cerebella, we found two to be particularly 
intriguing - collagen, type XVIII, alpha 1 (Col18a1) and cholecystokinin (Cck). 
First, the RNA-seq data revealed that both were expressed significantly higher in 
ATXN1[30Q]-D776 than in either ATXN1[82Q] and wt/FVB cerebella, suggesting 
they could have a role in a phenotype unique to the ATXN1[30Q]-D776 
cerebellum/PCs. Second, consistent with Col18a1and Cck contributing to the 
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molecular phenotype of PCs they both are among the top RNAs present in a 
bacTRAP translational profile of PCs (Heiman et al., 2008). Third, a mutation in 
COL18A1 was reported to segregate with a recessive neurological disorder that 
included ataxia in an Indian family (Paisán-Ruiz et al., 2009). In addition, a recent 
study found that Col18a1, specifically a proteolytic endostatin fragment of 
Col18a1, is necessary and sufficient to induce formation of climbing fiber 
synapses on PCs. In absence of Col18a1 CFs still targeted PCs and seem to 
extend along the PC dendritic tree, but failed to form synaptic terminals as 
assessed by the presence of VGlut2 puncta (Su et al., 2012). Moreover, Col1a1-/- 
mice also demonstrated ataxia as assessed by the rotarod (Su et al., 2012). The 
requirement of Col18a1/endostatin for the formation of CF/PC synaptic terminals 
suggests that overexpression of Col18a1 in ATXN[30Q]-D776 mice may 
contribute to the enhanced number of CF terminals found on ATXN[30Q]-D776 
PCs (Figure 3.11) (Ebner et al., 2013). Our finding that the reduced number of CF 
terminals on PC soma induced by ATXN1[30Q]-D776 in ATXN[30Q]-D776:Cck-/- 
mice indicates that Cck also has a role CF/PC synapse configuration. In many 
neurodegenerative diseases, synaptic dysfunction precedes cell death and 
correlates with development of neurological deficits (Wishart et al., 2006). The 
conclusion that Col18a1 and Cck have a role in CF/PC synapse organization 
along with the finding that both were downregulated in ATXN1[82Q] cerebella is 
consistent with them having a role in CF/PC dysfunction seen in ATXN1[82Q] 
SCA1 mice (Barnes et al., 2011). 
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Figure 3.11 
 
 
Figure 3.11: Diagram of the CF-PC synapses forming with absence or enhanced 
levels of Col18a1. Col18a1-/- PCs display a lack of synapses while ATXN1[30Q]-
D776 mice have twice as much Col18a1 and have increased levels of synapse 
formation. 
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RNA-seq splicing profile similarities in ATXN1[82Q] and ATXN1[30Q]-D776 
suggest abnormal splicing may cause ataxia in SCA1 
 
Analysis of the RNA-seq data revealed that ATXN1[82Q] and ATXN1[30Q]-D776 
cerebellar transcriptomes have a high number of splicing changes when 
compared to wt/FVB. Yet, there was essentially a complete overlap in RNAs that 
were alternatively spliced in ATXN1[82Q] and ATXN1[30Q]-D776 cerebella. 
While ATXN1 is known to interact with two splicing factors, RBM17 and U2AF65 
(de Chiara et al., 2009; Lim et al., 2008), its interaction with RBM17 is thought to 
be dependent on both polyQ tract length and phosphorylation status of S776 in 
that RBM17 interacts strongly with both ATXN1[82Q] and ATXN[30Q]-D776 (Lim 
et al., 2008). We suggest that the ability of ATXN1[82Q] and ATXN[30Q]-D776 to 
interact strongly with RBM17 is an important factor in the high degree of similarity 
found in the alternative splicing patterns of ATXN1[82Q] and ATXN[30Q]-D776 
cerebellar RNA.  
 
Conditional ATXN1[30Q]-D776 RNA-seq identified Anks1b isoform 3 mis-
splicing correlated with ataxia 
 
Applying RNA-seq analysis to a recently developed conditional ATXN[30Q]-D776 
transgenic line (Ebner et al., 2013), proved to an effective strategy for focusing in 
on RNAs with alterations in splicing that likely correlate with ataxia. Interestingly 
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of the 96 RNAs whose splicing returned to a wt pattern with recovery from ataxia, 
sixteen grouped into the synaptic function category by GO analysis, indicating 
further that synaptic dysfunction is key to the pathogenesis of ataxia in SCA1. 
Among the sixteen “synaptic” RNAs with a splicing pattern that returned to wt 
with recovery from ataxia in conditional ATXN1[30Q]-D776 cerebella, one, 
Anks1b, we propose is particularly intriguing.  
 
Anks1b, also know as amyloid b protein precursor intracellular domain 
associated protein-1 (AIDA-1), contains multiple conserved domains including 
ankyrin repeats, sterile alpha motif and a phosphor-tyrosine binding domain. 
Anks1b/AIDA-1 has a complex genomic organization with several isoforms 
generated by alternative splicing with the various isoforms having specific 
subcellular localization, function and binding partners. In this regard, it is of note 
that Anks1b was unique in our analysis in that it had multiple exons with 
alternative splicing. In particular was mouse isoform 3, which was found to have 
decreased expression in each of four SCA1 transgenic lines with ataxia. This 
isoform encodes a 510 amino acid protein highly similar to human isoform b 
(AIDA-1d in rat). AIDA-1d is reported to function in signaling from the synapse to 
nucleus in an activity dependent manner where it promotes protein synthesis 
regulating nucleolar assembly (Jordan et al., 2007).  
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The ability of a neuron to regulate and increase protein synthesis in response to 
persistent stimulation is suggested to be a critical process (Jordan et al., 2007). 
PCs do have to cope with a considerable level of stimulation from PF and CF 
synapses. The decrease in the amount of Anks1b isoform 3 seen with mutant 
ATXN1 expression could result in an inability to properly nucleolar numbers and 
protein synthesis in response to synaptic activity leading to PC dysfunction and 
ataxia. 
 
Pathway Analysis of condATXN1[30Q]-D776 RNA-seq Highlights Synaptic 
Changes 
 
The condATXN1[30Q]-D776 RNA-seq data was useful to narrow down potential 
targets that associated with ataxia. Pathway analysis identified axonal guidance 
signaling, synaptic long term depression (LTD) and synaptic long term 
potentiation (LTP) (Figure 3.10). This further emphasizes the importance of the 
synapse function, the development of ataxia and the potential to find targets to 
reverse ataxic phenotypes. 
 
 
 
 
 
 
   71 
 
 
 
 
 
 
 
 
 
Chapter 4: 
Recovery of Conditional ATXN1[30Q]-D776 Mice 
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Introduction 
 
Disease timecourse is well established in the SCA1 mouse model, ATXN1[82Q]. 
This model expresses full length human ATXN1 with 82 CAGs specifically in 
Purkinje cells driven by Purkinje cell-specific promoter Pcp2 (Burright et al., 
1995). ATXN1[82Q] animals initially show reduced cage behavior and develop 
ataxic cage behavior around 12 weeks of age. They also exhibit Rotarod and gait 
abnormalities suggestive of ataxic motor impairments as early as 5 weeks of age. 
In addition, pathological changes resemble patient phenotypes such as 
cerebellar atrophy and Purkinje cell loss (Clark et al., 1997), as well as 1H MRS 
biomarkers for neurochemical changes (Oz et al., 2010). However, pathological 
changes occur much later than neurological abnormalities suggesting PC 
dysfunction rather than cell death results in ataxia. 
 
Prior studies described the ability of conditional ATXN1[82Q] to recover from 
disease after halting expression of mutant ATXN1 (Zu et al., 2004). This study 
demonstrated dysfunctional neurons are able to recover if mutant ATXN1 
expression is blocked. However, the extent of recovery was decreased as 
animals increase in age. It is unclear if age dependence recovery is due to 
prolonged exposure to mutant ATXN1 or if older neurons are inherently less able 
to recover. In addition, delaying ATXN1 expression until after cerebellar 
development (which is completed 3 weeks after birth) greatly decreases disease 
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severity (Serra et al., 2006).  
Interestingly, adult mice expressing disease-causing forms of ATXN1 in their PCs 
display alterations in CF innervation of PCs that include a lack of CF terminals on 
PC secondary and tertiary dendrites and a reduction in the CF-PC synaptic 
strength (Barnes et al., 2011; Duvick et al., 2010). In particular, the increased 
number of CF terminals present on the PC soma in ATXN1[30Q]-D776 mice is 
reminiscent of the CF “pericellular nests” that form transiently during early 
postnatal cerebellar development (Altman, 1972).  
 
We set out to determine recovery profiles of ATXN1[30Q]-D776 mice since the 
progressive feature of disease is dependent on the presence of an expanded 
polyQ tract and these mice offer an opportunity to examine the regulation of CF 
innervation of PCs. This also allows us to assess the extent to which alteration 
PC-CF circuitry might contribute to disease. 
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Results 
 
Generation of a conditional SCA1 model 
 
We generated a conditional SCA1 model using the tetracycline-regulated system 
(Gossen and Bujard, 1992; Yamamoto et al., 2001). In the absence of 
tetracycline, the tetracycline transactivator (tTA) binds to tetracycline responsive 
elements (TRE), inducing expression of the respective downstream gene. In the 
presence of tetracycline or its derivative doxycycline (dox), the ability of the tTA 
protein to bind TRE sequences is abolished due to a conformational change in 
the tTA via the interaction of dox with the tTA. Thus, expression of the respective 
gene is suppressed (Figure 4.1). Conditional ATXN1[30Q]-D776 mice were 
generated by adding a point mutation to TRE-ATXN1[30Q] construct in order to 
substitute an aspartic acid for the serine at amino acid 776. These were cloned in 
the same manner as TRE-ATXN1[82Q] mice as previously described (Zu et al., 
2004). Embryo injections were performed by the Mouse Genetics Laboratory, 
University of Minnesota. PCR and Southern blot analyses were used to identify 
transgene positive animals. Pcp2-tTA mice (Zu et al., 2004) were crossed to 
TRE-ATXN1[30Q]-D776 mice to place both genes in a single mouse.  
 
 
   75 
 
 
Figure 4.1 
 
 
Figure 4.1: Tet-Off conditional model. Diagram of Tet-Off system used to design 
the condATXN1[30Q]-D776 conditional model. Tetracycline transactivator (tTA) 
expression was driven only in PCs by the PC specific promoter Pcp2. Active tTA 
binds to the tetracycline response elements (TRE) to induce expression of the 
ATXN1[30Q]-D776 transgene. The presence of doxycyclin inhibits expression of 
ATXN1[30Q]-D776 by binding to the tTA and inactivating it. 
 
 
 
 
 
tTA 
tTA 
Pcp2 Promoter tTA 
tTA 
- Doxycycline + Doxycycline 
ATXN1 expression ON ATXN1 expression OFF 
     PminCMV TRE  polyA      PminCMV TRE  polyA ATXN1-30Q-D776 ATXN1-30Q-D776 
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To determine which line to use for recovery experiments, initial characterization 
was performed on the two lines with the highest expression line 2 (L2) and line 3 
(L3), analyzed by qRT-PCR. Initial analysis by immunostaining was completed to 
ensure uniform expression in PCs (Figure 4.2). As both L2 and L3 had high and 
expression throughout the cerebellum, I tested the lines for ataxic behavior 
including motor function and hind stance width. Rotarod analysis indicated both 
lines were impaired compared to tTA/+ controls but not to nontransgenic FVB 
controls (Figure 4.3). In addition, hind stance width was increased in these lines 
(Figure 4.4). Since L2 had a greater Rotarod deficit and had a larger hind stance 
width I chose L2 to continue with future experiments. 
 
ATXN1[30Q]-D776 mice have high mRNA expression (Duvick et al., 2010). In an 
effort to increase conditional SCA1 mRNA levels, the mice were bred to 
homozygosity for the L2-TRE-ATXN1[30Q]-D776 transgene. The resulting mice, 
TRE-ATXN1[30Q]-D776/TRE-ATXN1[30Q]-D776;tTA/+ will henceforth be 
referred to as condATXN1[30Q]-D776. As illustrated and discussed below 
(Figure 4.6C), condATXN1[30Q]-D776 expressed lower levels of the transgene 
than ATXN1[30Q]-D776. 
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Figure 4.2 
 
Figure 4.2: ATXN1 expression in condATXN1[30Q]-D776 cerebella.  
Immunostaining of ATXN1 (red) and Purkinje cells (green, calbindin) to assess 
uniform expression of the transgene in the cerebellum. 
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Figure 4.3 
 
 
Figure 4.3: Motor coordination deficits in condATXN1[30Q]-D776 lines. Line 2 
and Line 3 of the conditional model show deficits by Rotarod analysis compared 
to the tTA control. 
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Figure 4.4 
 
Figure 4.4: Hind Stance width in condATXN1[30Q]-D776 lines. Line 2 and Line 3 
of the conditional model show greater hind stance width compared to the tTA 
control. 
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As shown in Fig. 4.3 and 4.4, the tTA transgene, for some unknown reason, 
conferred some improvement to Rotarod ability and hindstance width, which is 
also seen in the condATXN1[30Q]-D776 lines (hemizygous for the tTA 
transgene). Therefore, I chose tTA/+ as my control line to account for these 
differences in behavior. 
 
The ability of dox to turn off gene expression in condATXN1[30Q]-D776 mice was 
assessed by giving 12-16 week old mice dox in their drinking water. Animals 
were sacrificed at 24 hours, 7 days, and 6 weeks post treatment. Total RNA was 
isolated from the cerebella and ATXN1 levels were analyzed by qRT-PCR. Dox 
administration via drinking water was successful in turning ATXN1 expression off 
after 24 hours and successive treatment for 6 weeks showed no increase in 
expression after long-term exposure (Figure 4.5). 
 
 
Expression of mutant ATXN1 during development enhances disease 
 
 
The first three postnatal weeks in mice are critical for PC and cerebellar 
development. During this time, a major input to PC called climbing fibers (CFs) 
mature from the inferior olive. The majority of PCs are innervated by a single CF 
whose synapses are located on the PC’s primary, secondary, and tertiary 
dendrites.  In addition, the cerebellum increases in size and transforms into a 
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highly foliated structure (Goldowitz and Hamre, 1998). Previous work indicated 
that blocking ATXN1[82Q] expression during development prevents neurological 
and pathological features that occur in animals expressing ATXN1[82Q] during 
postnatal development (Serra et al., 2006).  
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Figure 4.5 
 
 
 
Figure 4.5: ATXN1 expression in condATXN1[30Q]-D776 after dox 
administration. Graph of qRT-PCR mRNA levels showing sustained loss of 
ATXN1[30Q]-D776 after dox administration for 1 day to 6 weeks. Error bars 
indicate SEM. 
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To determine if the changes observed at CF-PC synapses in ATXN1[30Q]-D776 
mice reflect the affect of ATXN1 expression during a critical period of 
development we utilized the condATXN1[30Q]-D776 model. For these studies, 
we examined CF extension using cerebellar sections from three groups of mice.  
The gene on control group, expressed condATXN1[30Q]-D776 from birth until 
they were sacrificed at 7 weeks of age (Figure 4.6A).  The gene off/gene on 
group was treated with doxycycline from birth until p21, at which time the gene 
was turned on and expressed for an additional 7 weeks of age (Figure 4.6A). 
Using this strategy, both groups of mice express condATXN1[30Q]-D776 for 7 
weeks. Cerebellar sections labeled with calbindin and VGLUT2 from mice in the 
gene on group, showed a high degree of both PC and CF terminal atrophy 
(Figure 4.6A).  Conversely, cerebellar sections from mice in the gene off/gene on 
group showed healthy PC dendrites with a high density of CF terminals (Figure 
4.6A). CF extension reached an average of 52% in the gene on 
condATXN1[30Q]-D776 mice, notably lower than in ATXN1[30Q]-D776 mice 
used in the previous studies (Figure 4.6B). The CF extension in the gene on 
condATXN1[30Q]-D776 mice was significantly different from both the gene off/ 
gene on mice and the gene off mice (p<0.01 and  p< 0.001, ANOVA followed by 
Bonferroni post hoc test). In the gene off/gene on mice, the CF terminals 
extended to a greater degree, 70%, and was not significantly different from 
condATXN1[30Q]-D776 gene off mice (p > 0.05, ANOVA followed by Bonferroni 
post hoc test) (Figure 4.6B), suggesting that ATXN1[30Q]-D776 affects CF 
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extensions during development when the distal CF terminals are being 
established.  
 
Of note is the differences observed between the ATXN1[30Q]-D776 and 
condATXN1[30Q]-D776 mice. ATXN1[30Q]-D776 mice retain CF synapses on 
the PC soma to a remarkable extent, while in condATXN1[30Q]-D776 mice CF-
PC somatic synapses were not evident (data not shown).  Further, CF extension 
in condATXN1[30Q]-D776 mice at 7 weeks of age was lower than that in 
ATXN1[30Q]-D776 mice at any age. Considering that mutant ATXN1 expression 
during development was critical for affecting the CF-PC synapses (Figure 4.6), 
we examined the developmental expression of the respective transgenes at p7, 
p9, p11, and p14. The expression of condATXN1[30Q]-D776 mRNA was 
relatively constant through development (Figure 4.6C).  Alternatively, 
ATXN1[30Q]-D776 mice expression rises dramatically between p9 and p11 
(Figure 4.6C). This data further supports the hypothesis that mutant ATXN1 
expression during development is critical for the alteration of CF-PC synapse and 
that the specific timing of expression during development alters the phenotypic 
profile. 
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Figure 4.6 
 
Figure 4.6: CF-PC Extension is Restored when ATXN1[30Q]-D776 is Not 
Expressed During Cerebellar Development (A) 60X immunofluorescent images 
from primary fissure showing restored PC morphology (red) and CF extension 
(green) in mice not expressing ATXN1[30Q]-D776 during the first three weeks of 
age. (B) Graph of distal extension of CF terminals onto the PC dendrites in 
conditional ATXN1[30Q]-D776 mice. Conditional ATXN1[30Q]-D776 Off  N=4; 
Conditional ATXN1[30Q]-D776 Off-On N= 3 animals; Conditional ATXN1[30Q]-
D776 On N = 4. (C) Graph of ATXN1 expression during development in 
ATXN1[30Q]-D776/+ and conditional ATXN1[30Q]-D776, ATXN1[82Q]-S776, 
and ATXN1[30Q]-D776-K772T/+mice. Data are normalized to ATXN1 expression 
of ATXN1[30Q]-D776/+ mice at p7.  *p<0.05, **p<0.01, ***p<0.001. 
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Disease reversal: early stage disease 
 
The ability of condATXN1[30Q]-D776 mice to recover after cessation of 
transgene expression was assessed at early, mid and late stages of disease. For 
the early disease stage animals were allowed to age for 6 weeks with the 
condATXN1[30Q]-D776 gene on. Animals were assessed for any neurological 
phenotype on the Rotarod apparatus. At six weeks the condATXN1[30Q]-D776 
animals were significantly impaired at each day tested (Figure 4.7). The group of 
animals was then split in half; the gene off group was administered dox and 
sucrose, and the control gene on group received sucrose only. At 12 weeks the 
animals were tested for Rotarod performance a second time. 6 week-old mice 
allowed to age an additional 6 weeks with the gene on displayed a Rotarod 
deficiency, though the animals’ ability did not progressively deteriorate over the 
6-12 week time period (Figure 4.7). 
 
In contrast, condATXN1[30Q]-D776 animals treated with dox for 6 weeks perform 
as well as Pcp2-tTA/+ controls. This data is similar to historical data, in which 
conditional ATXN[82Q] animals (cSCA1) could recover after expressing ATXN1 
for only 6 weeks (Figure 4.7 dark gray bars). However, the condATXN1[30Q]-
D776 animals treated with dox recover equally to wild-type counterparts and 
cSCA1 recover to 84.5% of wild-type (Zu et al., 2004). 
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Purkinje cells at early stage disease show signs of moderate pathology including 
dendritic atrophy as measured by reduced molecular layer thickness after 
calbindin immunostaining (Figure 4.8, quantified in Figure 4.7B). In addition, CF 
extension is reduced from wild-type levels and disease severity was rated at a 
moderate level (Figure 4.8, quantified in Figure 4.7C and D). Interestingly, after 
turning the gene off for 6 weeks these measures do not significantly improve 
even though animals completely recover the ataxic phenotype as measured by 
Rotarod analysis. It may be that at this age point that only PC dysfunction is 
rescued after turning the gene off. Alternatively, since the histological 
abnormalities are relatively minor at this age we may not have sensitive enough 
measures to quantify any rescue of pathology. 
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Figure 4.7 
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Figure 4.7: Early stage disease recovery. (A) Restoration of a normal 
performance level on the Rotarod in condATXN1[30Q]-D776 mice treated with 
dox beginning at 6 weeks of age. Quantified histological graphs of molecular 
layer length (B), distal extension of CF terminals onto the PC dendrites (C) and 
severity scores (D) in condATXN1[30Q]-D776 6 weeks with gene on and 6 weeks 
of indicated treatment. Dotted line indicates Pcp2 tTA/+  treated with dox (WT 
control) levels. Error bars indicate SEM. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4.8 
 
 
Figure 4.8: Early stage disease histology in condATXN1[30Q]-D776 cerebella. 
Immunofluorescent images of the primary fissure showing minor pathology in 
condATXN1[30Q]-D776 including slight molecular layer thinning and decreased 
CF extension. PC pathology measured by calbindin staining (red) and CF 
extension measured by VGLUT2 staining (green). 
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Disease reversal: mid stage disease 
 
For the mid disease stage animals were allowed to age for 16 weeks with the 
cATXN1[30Q]-D776 gene on. At 16 weeks animals were assessed for baseline 
neurological phenotype on the Rotarod apparatus. After 16 week behavioral 
testing, the group of animals was split in half; the gene off group was 
administered dox and sucrose, and the control gene on group received sucrose 
only. At 20 and 24 weeks the animals were tested for Rotarod performance a 
second and third time. At 16, 20 and 24 weeks the condATXN1[30Q]-D776 gene 
on animals were significantly impaired compared to tTA controls (Figure 4.9A). 
However, after dox treatment for 4 weeks animals recover Rotarod defects 
completely. This trend continues after 8 weeks of treatment, though by student t-
test comparing 8 weeks of dox treatment cohort to 8 weeks of sucrose treatment 
cohort is not significant. This may be due to variability in animal performance 
after repeated rounds of Rotarod testing as animal’s inherent fear of falling from 
the Rotarod and test compliance reduces. The ability of the condATXN1[30Q]-
D776 to recover at 16 weeks is a significant change from previous data in which 
cSCA1 mice were able to recover partially (about 60% of WT controls) at a 
slightly earlier time point of 12 weeks. In addition, improvement was significantly 
better than sucrose treated controls only after 12 weeks of dox treatment as 
opposed to condATXN1[30Q]-D776 improvement after 4 weeks of dox treatment 
(Figure 4.9A gray bars). 
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At mid-stage disease restoration of a normal neurological phenotype correlated 
with a reversal of PC pathology (Figure 4.10). At 16 weeks, CF extension is 
dramatically reduced (Figure 4.9B and Figure 4.10). This extension returns after 
4 weeks of dox treatment and continues to improve with longer treatment of 8 
and 12 weeks (Figure 4.9B and Figure 4.10). Molecular layer thickness also 
improves over the duration of treatment and severity scores significantly improve. 
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Figure 4.9 
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Figure 4.9: Mid stage disease recovery. (A) Restoration of a normal performance 
level on the Rotarod in condATXN1[30Q]-D776 mice treated with dox beginning 
at 16 weeks of age. Quantified histological graphs of molecular layer length (B), 
distal extension of CF terminals onto the PC dendrites (C) and severity scores 
(D) in condATXN1[30Q]-D776 16 weeks with gene on and 4-12 weeks of 
indicated treatment. Dotted line indicates Pcp2 tTA/+  treated with dox (WT 
control) levels. Error bars indicate SEM. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4.10 
 
 
Figure 4.10: Mid stage disease histology in condATXN1[30Q]-D776 cerebella. 
Immunofluorescent images of the primary fissure showing minor pathology in 
condATXN1[30Q]-D776 including slight molecular layer thinning and decreased 
CF extension. PC pathology measured by calbindin staining (red) and CF 
extension measured by VGLUT2 staining (green). 
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Disease reversal: late stage disease 
 
 
For the late disease stage animals were allowed to age for 32 weeks with the 
cATXN1[30Q]-D776 gene-on. At 32 weeks animals were assessed for baseline 
neurological phenotype on the Rotarod apparatus. After 32 week behavioral 
testing, the group of animals was split in half; the gene off group was 
administered dox and sucrose, and the control gene-on group received sucrose 
only. At 36, 40 and 44 weeks the animals were tested for Rotarod performance. 
At all ages the condATXN1[30Q]-D776 gene-on animals were significantly 
impaired compared to tTA controls (Figure 4.11A). In addition, dox treatment for 
4-12 weeks does not result in a significant improvement in Rotarod performace.  
 
Though ataxia persisted in late-stage animals even after ATXN1 expressed 
ceased, some aspects of PC pathology improved. Molecular layer thickness 
improved after 4 and 8 weeks of dox treatment, though thickness continued to 
decrease even with treatment until after 12 weeks of dox treatment there was no 
longer a significant increase in molecular layer thickness compared to 32 weeks 
gene-on. In addition, CF extension is dramatically reduced and did not 
significantly recover at any point in the treatment. Histology measurements were 
complicated by the fact that calbindin, a marker for PCs (Barski et al., 2003), was 
extensively downreguated resulting in poor PC staining. After treatment with dox, 
calbindin mRNA levels moderately recovered, which resulted in better imaging of 
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the cerebellar structure and PCs suggesting that lack of PC staining was a result 
of downregulation and not the loss of PCs from the molecular layer. In addition, 
while severity scores decreased after only 4 weeks of dox treatment, additional 
treatment time did not further improve disease severity. 
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Figure 4.11 
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Figure 4.11: Late-stage disease recovery. (A) Abnormal performance level on 
the Rotarod in condATXN1[30Q]-D776 mice treated with dox beginning at 32 
weeks of age. Histological graphs of molecular layer length (B), distal extension 
of CF terminals onto the PC dendrites (C) and severity scores (D) in 
condATXN1[30Q]-D776 32 weeks with gene on and 4-12 weeks of indicated 
treatment. Dotted line indicates Pcp2 tTA/+  treated with dox (WT control) levels. 
Error bars indicate SEM. 
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Figure 4.12 
 
Figure 4.12: Late stage disease histology in condATXN1[30Q]-D776 cerebella. 
Immunofluorescent images of the primary fissure showing pathology in 
condATXN1[30Q]-D776 including molecular layer thinning and decreased CF 
extension and decreased calb immunostaining. PC pathology measured by 
calbindin staining (red) and CF extension measured by VGLUT2 staining (green). 
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Discussion 
 
Conditional Model of ATXN1[30Q]-D776 
 
I developed a conditional model of ATXN1[30Q]-D776 using a tet-off system to 
control expression of the transgene in PCs. Similar to previous results (Zu et al., 
2004), the pathogenic effects of ATXN1[30Q]-D776 could be reversed after 
cessation of gene expression with dox treatment. I examined the ability of PCs to 
recover at three stages of disease. This included an early stage after 6 weeks, 
mid-stage after 16 weeks and late-stage at 32 weeks. In addition, I examined the 
effects of condATXN1[30Q]-D776  expression during development. 
 
CF Development Altered by condATXN1[30Q]-D776 Expression Pattern 
 
Normally, early in the postnatal life of a mouse each PC soma is innervated by 
multiple CFs from different inferior olivary neurons. During the first postnatal 
week the somatic synapses of one CF functionally become stronger (Hashimoto 
and Kano, 2003). Subsequently, the terminals of this strong CF translocate up 
from the cell body and along the proximal PC dendritic shaft. During the late 
phase in development, the dominant CF begins its climb up the PC dendritic tree. 
During the second postnatal week, the synapses on the PC soma from both the 
dominant and other weaker CFs are eliminated. By the end of the third postnatal 
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week one CF forms hundreds of synapses along a PC primary dendrite, with 
essentially no synapses remaining on the PC soma (Cesa and Strata, 2009; 
Kano and Hashimoto, 2009).  
 
The capacity of ATXN1 to disrupt CF innervation is shown here to depend upon 
the timing of ATXN1 expression during development. In ATXN1[30Q]-D776 
cerebella, CF translocation is normal at p14 and subsequently CF terminals fail to 
translocate beyond that point and the number of CF synapses on PC somata 
remain high. The failure of CFs to develop properly after p14 is synchronized with 
the expression of ATXN1[30Q]-D776 increasing dramatically after p9. During this 
period, the late phase CF development has begun and ATXN1[30Q]-D776 
expression altered the normally proceeding CF translocation and CF synapse 
elimination. Further, using a condATXN1[30Q]-D776 model we show that by 
delaying expression until p21, CF extension is restored compared with mice that 
express ATXN1 during development, supporting the hypothesis that ATXN1 
expression during development alters CF–PC innervation. Unlike the 
ATXN1[30Q]-D776 model, condATXN1[30Q]-D776 mice express ATXN1 as early 
as p7 and these mice display a dramatically decreased CF extension compared 
with the other SCA1 models. The expression of ATXN1 at p7 in conditional 
ATXN1[30Q]-D776 mice resulted in improved CF–PC somatic synapse 
elimination. These data reinforce the hypothesis that the altered CF development 
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is dependent upon the temporal pattern of ATXN1 expression during 
development. 
 
Early Stage Disease Recovery 
 
At the early stage, condATXN1[30Q]-D776  animals completely recovered any 
ataxic phenotype by cage behavior and rotarod analysis (Figure 4.7A). At this 
stage of disease, there was mild PC including a reduced molecular layer 
thickness and a decrease in CF extension. The reduced molecular layer 
thickness at this age is a characteristic of the ATXN1[30Q]-D776 model in that 
the molecular layer never fully reaches wild type thickness, but also does not 
progressively decrease in thickness (data not shown). Altered distribution of CFs 
on PCs is another characteristic feature of ATXN1[30Q]-D776 (Duvick et al., 
2010). Therefore, these phenotypes were anticipated. Interestingly, despite the 
reversal of ataxia, using measurements of molecular layer, CF extension and 
severity scores, I could not find any significant difference in pathology after 6 
weeks of dox treatment. Objectively, after examining a minimum of three 
cerebella from each cohort I found there to be a slight difference, but it could be 
the increase in calbindin staining after dox treatment rather than reversal of 
pathology. It may also be that the pathology was not extensive enough at this 
time-point to see any change after gene cessation. 
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Mid Stage Disease Recovery 
 
At 16 weeks, condATXN1[30Q]-D776  had significant pathology (Figure 4.9). 
Some animals had areas where CF extension appeared normal, and other areas 
where there were no VGLUT2 positive stained CF to measure. After 
quantification, the CF extension as a percentage of the molecular layer ranged 
from 0-42% with an average of 22%. The molecular layer was also significantly 
reduced from Pcp2-tTA/+ controls. However, despite the level pathology when 
dox treatment was started, condATXN1[30Q]-D776  mice were able to 
completely recover all Rotarod deficits and performed the task as well as controls 
after only 4 weeks of treatment. The recovery correlated with an increased 
molecular layer, an increase in CF extension and a decrease in severity scores. 
The neurological improvement continued as the longer the animals were given 
dox, from four to twelve weeks, the better the scores. 
 
The extent of the condATXN1[30Q]-D776  to recover at this time point is 
markedly different than condATXN1[82] mice (Zu et al., 2004). When 
condATXN1[82] mice were examined at 12 weeks of age, followed by four to 
twelve weeks of dox treatment, they exhibited only partial recovery. By Rotarod 
analysis, condATXN1[82] significantly improved from sucrose only controls but 
only recovered to roughly 60% of wild-type controls and it took eight weeks of 
treatment to see an improvement and did not see further Rotarod improvement 
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when treated for the full twelve weeks. This is as opposed to the 
condATXN1[30Q]-D776 which recovered to almost 100% of the controls after 
only four weeks of dox treatment. In addition, it took twelve weeks of dox 
treatment in condATXN1[82Q] to see a significant increase in molecular layer 
thickness as opposed to the condATXN1[30Q]-D776 which saw improvements 
after four. 
 
Late Stage Disease Recovery 
 
Somewhat surprisingly, despite a lack of PC death, condATXN1[30Q]-D776 mice 
in which transgene expression was halted by dox after 32 weeks of age still had 
coordination deficits by cage behavior and performed poorly on the Rotarod as 
compared to Pcp2-tTA/+ controls. There was a trend for the dox treated cohort to 
perform better by accelerating Rotarod, however the improvement never reached 
statistical significance. There were also some signs of improved neurological 
phenotype, including a slight increase in molecular layer after four and eight 
weeks of treatment, and a decrease in severity scores after eight weeks of dox 
administration. In addition, CF extension trended upward but also never reached 
significance. There was also no correlation with longer dox treatment and better 
performance or neurological status. 
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PC Recovery Impacted by Age Despite Lack of polyQ Tract 
 
Prior studies described the ability of conditional ATXN1[82Q] to recover from 
disease after halting expression of mutant ATXN1 (Zu et al., 2004). Generally, 
the results support prior findings that coordination and PC pathology are 
reversible (Yamamoto et al., 2000; Zu et al., 2004). However, the extent of 
recovery was decreased as animals increase in age. Similarly, younger 
condATXN1[30Q]-D776 mice were more able to recover motor deficits and 
neurological pathology. However, even at a slightly later time point, sixteen 
weeks as opposed to twelve, the condATXN1[30Q]-D776 were more able to 
recover from disease than previous studies using condATXN1[82Q] mice. 
Despite the ability of condATXN1[30Q]-D776 mice to recover completely at mid-
stage disease, once disease was allowed to progress to 32 weeks mice were 
markedly less able to recover.  
 
It was previously unclear if age dependence recovery was due to prolonged 
exposure to the polyQ expansion in mutant ATXN1, or if older neurons are 
inherently less able to recover. This was also complicated by late-stage disease 
features in condATXN1[82Q] mice such as the onset of PC death. The 
advantage of using condATXN1[30Q]-D776 to assess recovery was that they do 
not have progressive features of disease such as PC death and provided a way 
to tease apart the previous question. The recovery profile of condATXN1[30Q]-
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D776 suggests that PCs have a sustained ability to recover but there is a limit to 
recovery that is unaffected by the presence or absence of an expanded polyQ 
tract. Rather, it seems that age is the primary factor influencing recovery. It may 
be older neurons are less able to respond or alter gene expression needed for 
recovery. 
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Chapter 5: Discussion 
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Major Findings 
 
The use of RNA-sequencing provided a non-biased molecular approach to 
examine the cerebellar transcriptome of ATXN1[82Q] and ATXN1[30Q]-D776 
relative to wt/FVB. Perhaps the most substantial finding of my thesis work was 
how similar the ATXN1[82Q] and ATXN1[30Q]-D776 models were by both gene 
expression and splicing analysis. In both cases, most of the genes were 
downregulated compared to wt/FVB gene levels similar to previous SCA1 gene 
expression studies (Crespo-Barreto et al., 2010; Lin et al., 2000; Serra, 2004). In 
addition, there was extensive overlap in the gene lists for splicing and gene 
expression, 4615 and 4459 overlapping genes respectively. This led to 
subsequent identification of similar pathways and networks. 
 
These findings emphasize how important ATXN1 native function is for the SCA1 
disease process. As previously discussed, ATXN1 interacts with a variety of 
nuclear components including RNA, regulators of transcription and proteins 
involved in RNA processing. Clearly, phosphorylation status of ATXN1 at serine 
776 dramatically impacts the function of ATXN1, leading to many expression 
changes, as well as altering splicing. Additionally, this suggests the ATXN1[30Q]-
D776 protein is involved in SCA1 pathology in a similar mechanism as 
ATXN1[82Q], and not causing disease or ataxia via a distinct pathway. This also 
gives credibility to using ATXN1[30Q]-D776 as a model of SCA1, and suggests 
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the aspartic acid substitution is mimicking the normal phosphorylation process. 
 
While phosphorylation at site 776 modulates the stability of ATXN1, it also 
increases the level of RBM17 binding. A phosphomimetic aspartic acid mutation 
at this site increases the interaction with RBM17 to levels comparable to 
ATXN1[82Q]. Thus, I hypothesize that ATXN1 binding of RBM17, which leads to 
alternative splicing of RBM17 targets, is a major factor in the disease process. 
This mechanism is illustrated in Figure 5.1. I used Anks1b to demonstrate the 
splicing similarities in ATXN1[82Q] and ATXN1[30Q]-D776. In fact, every SCA1 
model tested showed a decrease in Anks1b isoform 3. However, it remains to be 
seen if Anks1b is a target of RBM17 alternative splicing regulation. 
 
I observed implications for climbing fiber and synapse abnormalities in SCA1 
disease throughout my experiments. Using RNA-sequencing, I identified several 
interesting targets, including Cck and Col18a1 as candidate genes for disease 
aspects that differ between ATXN1[82Q] and ATXN1[30Q]-D776. Both were 
involved in synapse maintenance or formation. Col18a1, and its proteolytically 
derived fragment endostatin, are necessary and sufficient for proper formation of 
CF synapses on the dendrites of PCs. In addition, my studies using a genetic 
approach to ablate Cck expression show a reduced number of CF puncta on the 
PC body. My condATXN1[30Q]-D776 recovery studies illustrated that PC 
recovery diminishes over time. Interestingly, recovery is unaffected by the 
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presence or absence of an expanded polyQ tract. Rather, it seems that age is the 
primary factor influencing recovery. It is important to note that CF extension was 
one measurement that clearly improved at mid stage disease, but did not recover 
at later stages. Similarly, Anks1b isoform 3 reported to function in signaling from 
the synapse to nucleus in an activity dependent manner where it promotes 
protein synthesis regulating nucleolar assembly. 
 
A major hallmark of SCA1 disease death is cerebellar atrophy caused by PC 
dendritic pruning and eventual cell death. However, my findings support the idea 
that PC dysfunction, and PC interaction with CF and other cerebellar cell types, is 
much more central to the disease process than previously appreciated. Thus, in 
order to develop successful therapies for SCA1 in the future, it will be essential to 
target the native function of ATXN1. 
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Figure 5.1 
 
 
Figure 5.1: Model of ATXN1 disease mechanism. Phosphorylation status 
impacts ATXN1 stability and RBM17 binding. The ATXN1-RBM17 complex leads 
to alternative splicing and ataxia. An expanded PolyQ tract inhibits ATXN1 
nuclear export as well as increasing RBM17 binding. 
 
  
   113 
 
Future Directions 
 
For the RNA-sequencing experiments, I used ATXN1[82Q], ATXN1[30Q]-D776, 
and condATXN1[30Q]-D776 whole cerebella. While the transgenes were 
overexpressed specifically in the PCs, the gene expression and splicing findings 
illustrated here could be direct effects from PCs as well as nonautonomous 
effects from other cell types in the cerebellum. I attempted to address these 
concerns by filtering my datasets though a list of 1000 PC enriched mRNA 
(Heiman et al., 2008) and by using Allen Brain Atlas in situ hybridization to 
examine mRNA localization (Lein et al., 2007). Now that we have several targets 
there are other methods we could use to ascertain direct verses non-direct 
effects including laser microdisection microscopy and using a bacTRAP mouse 
model. We could use laser microdisection to collect tissue from the PC layer only 
or the entire molecular layer (to include PC dendrites), and use RNA collected 
from the tissue to measure splicing and gene expression changes. Alternatively, 
we could use the bacTRAP, translating ribosome affinity purification, approach to 
study translated mRNAs in PCs (Doyle et al., 2008; Heiman et al., 2008). In this 
way, we could use Pcp2-bacTRAP mice crossed to used ATXN1[82Q] and 
ATXN1[30Q]-D776 mice to examine only actively translated mRNA from PCs and 
look for gene expression and splicing changes identified by the RNA-seq. 
 
Another question that remains to be answered is how does ATXN1 regulate the 
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gene changes we see in the RNA-seq data? As previously mentioned, ATXN1 
interacts with several regulators of transcription including SMRT (Tsai et al., 
2004), Capicua (Kim et al., 2013; Lam et al., 2006), Gfi-1 (Tsuda et al., 2005), 
and the Rora/Tip60 complex (Gehrking et al., 2011; Serra et al., 2006). The Orr 
lab is currently generating ATXN1[82Q] transgenic mice in which the binding 
sites for Capicua is mutated. It will be intriguing to see in these mice if Cck or 
Col18a1 levels are altered in these models to better understand the role of 
Capicua as a transcription factor for these genes. 
 
Finally, the initial goal of this project was to identify molecules and pathways 
specific to progressive disease in SCA1 including PC death. While the RNA-seq 
studies lead to the discovery of several potential targets and led to the discovery 
that splicing correlates with ataxia in our models, I could not identify any specific 
molecules or pathways that lead to cell death in PCs expressing ATXN1[82Q]. It 
may be that our choice to study animals at 12 weeks, when ataxia is present but 
PC pathology is relatively intact hampered these efforts. Future aging studies are 
planned for the ATXN1[30Q]-D776;Cck-/- mice to examine how Cck expression 
levels impact disease progression including assessing motor ability by Rotarod 
and examining pathology at one year of age.  
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Appendix 1. CuffDiff Data from ATXN1[82Q] vs ATXN1[30Q]-D776 
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